Руководство по лечению тяжелого периоперационного кровотечения: рекомендации Европейского общества анестезиологов
Аннотация
Выбор наиболее подходящей стратегии лечения пациентов с периоперационным кровотечением — сложная и многоступенчатая задача. Изначально необходимо определить, существует ли у пациента повышенный риск развития периоперационного кровотечения. Затем, в целях профилактики развития кровотечения, необходимо провести предоперационную коррекцию анемии, а также стабилизацию макроциркуляции и микроциркуляции, чтобы создать оптимальные условия для переносимости кровотечения. Наконец, для уменьшения кровопотери вследствие развития интраоперационных и послеоперационных кровотечений, во избежание развития осложнений или смертельного исхода должны быть применены методы целевого вмешательства. В настоящем обновлении руководства представлен обзор наиболее актуальной информации, которая может помочь медицинскому персоналу улучшить стратегию терапии таких пациентов. Для поиска информации в данном обновлении были использованы электронные базы данных, составленные на всех языках мира, начиная с 2011 г. или 2012 г. (в зависимости от условий поиска) и заканчивая 2015 г. В ходе данного поиска были отобраны 18 334 статьи. В поисках новых методов были изучены все статьи, а также пересмотрены существующие рекомендации 2013 г. В рекомендациях 2013 г. были отредактированы некоторые формулировки, изменена градация рекомендаций по степени значимости, а также были добавлены новые рекомендации. Предварительная версия рекомендаций была опубликована на сайте Европейского общества анестезиологов (European Society of Anaesthesiology — ESA) и была доступна для рассмотрения в течение четырех недель. Все комментарии были учтены, а соответствующие поправки внесены в данную версию.
Об авторах
S. A. Kozek-LangeneckerРоссия
Sibylle A. Kozek-Langenecker
А. B. Ahmed
Россия
Aamer B. Ahmed
A. Afshari
Россия
Arash Afshari
P. Albaladejo
Россия
Pierre Albaladejo
C. Aldecoa
Россия
Cesar Aldecoa
G. Barauskas
Россия
Guidrius Barauskas
E. De Robertis
Россия
Edoardo De Robertis
D. Faraoni
Россия
David Faraoni
D. C. Filipescu
Россия
Daniela C. Filipescu
D. Fries
Россия
Dietmar Fries
T. Haas
Россия
Thorsten Haas
M. Jacob
Россия
Matthias Jacob
M. D. Lance´
Россия
Marcus D. Lance´
J. V.L. Pitarch
Россия
Juan V.L. Pitarch
S. Mallett
Россия
Susan Mallett
J. Meier
Россия
Jens Meier
Z. L. Molnar
Россия
Zsolt L. Molnar
N. Rahe-Meyer
Россия
Niels Rahe-Meyer
Ch. M. Samama
Россия
Charles M. Samama
J. Stensballe
Россия
Jakob Stensballe
P. J.F. Van der Linden
Россия
Philippe J.F. Van der Linden
A. Wikkelsø
Россия
Anne J. Wikkelsø
P. Wouters
Россия
Patrick Wouters
P. Wyffels
Россия
Piet Wyffels
K. Zacharowski
Kai Zacharowski
Список литературы
1. De Robertis E., Longrois D. To streamline the guideline challenge: The European Society of Anaesthesiology policy on guidelines development. Eur J Anaesthesiol. 2016; 33: 794–9.
2. Kozek-Langenecker S.A., Afshari A., Albaladejo P., et al. Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013; 30: 270–382.
3. Farmer S.L., Towler S.C., Leahy M.F., Hofmann A. Drivers for change: Western Australia Patient Blood Management Program (WA PBMP), World Health Assembly (WHA) and Advisory Committee on Blood Safety and Availability (ACBSA). Best Pract Res Clin Anaesthesiol. 2013; 27: 43–58.
4. Musallam K.M., Tamim H.M., Richards T., et al. Preoperative anaemia and postoperative outcomes in noncardiac surgery: A retrospective cohort study. Lancet. 2011; 378: 1396–1407.
5. Koch C.G., Li L., Sun Z., et al. Hospital-acquired anemia: Prevalence, outcomes, and healthcare implications. J Hosp Med. 2013; 8: 506–12.
6. Marik P.E., Corwin H.L. Efficacy of red blood cell transfusion in the critically ill: A systematic review of the literature. Crit Care Med. 2008; 36: 2667–74.
7. Shander A, Goodnough LT. Why an alternative to blood transfusion? Crit Care Clin. 2009; 25: 261–277.
8. Vamvakas E.C., Blajchman M.A. Transfusion-related mortality: The ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009; 113: 3406–17.
9. Clauss A. Rapid physiological coagulation method in determination of fi brinogen. Acta Haematol. 1957; 17: 237–46.
10. Solomon C., Baryshnikova E., Tripodi A., et al. Fibrinogen measurement in cardiac surgery with cardiopulmonary bypass: Analysis of repeatability and agreement of Clauss method within and between six different laboratories. Thromb Haemost. 2014; 112: 109–17.
11. Gielen C., Dekkers O., Stijnen T., et al. The effects of pre and postoperative fi brinogen levels on blood loss after cardiac surgery: A systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2014; 18: 292–8.
12. Whiting P., Al M., Westwood M., et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: A systematic review and cost-effectiveness analysis. Health Technol Assess. 2015; 19: 1–228.
13. Erdoes G., Gerster G., Colucci G., et al. Prediction of postweaning fibrinogen status during cardiopulmonary bypass: An observational study in 110 patients. PLoS ONE. 2015; 10: e0126692.
14. Theusinger O.M., Schroder C.M., Eismon J., et al. The influence of laboratory сoagulation tests and clotting factor levels on Rotation Thromboelastometry (ROTEM(R)) during major surgery with hemorrhage. Anesth Analg. 2013; 117: 314–21.
15. Lind S.E., Boyle M.E., Fisher S., et al. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. Am J Clin Pathol. 2014; 141: 665–74.
16. Kim B., Quan M.-L., Goh R.-Y., et al. Comparison of prolonged prothrombin and activated partial thromboplastin time results with thrombelastograph parameters. Lab Med. 2013; 44: 319–23.
17. Agren A., Wikman A.T., Holmstrom M., et al. Thromboelastography (TEG1) compared to conventional coagulation tests in surgical patients – a laboratory evaluation. Scand J Clin Lab Invest. 2013; 73: 214–20.
18. Acedillo R.R., Shah M., Devereaux P.J., et al. The risk of perioperative bleeding in patients with chronic kidney disease: A systematic review and meta-analysis. Ann Surg. 2013; 258: 901–13.
19. Lopes C.T., Dos Santos T.R., Brunori E.H., et al. Excessive bleeding predictors after cardiac surgery in adults: Integrative review. J Clin Nurs. 2015; 24: 3046–62.
20. Levy J.H., Szlam F., Wolberg A.S., Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: A review of the literature and current guidelines for testing. Clin Lab Med. 2014; 34: 453–77.
21. Dutzmann S., Gessler F., Marquardt G., et al. On the value of routine prothrombin time screening in elective neurosurgical procedures. Neurosurg Focus. 2012; 33: E9.
22. Townsend J.C., Heard R., Powers E.R., Reuben A. Usefulness of international normalized ratio to predict bleeding complications in patients with end-stage liver disease who undergo cardiac catheterisation. Am J Cardiol. 2012; 110: 1062–5. 2
23. Huang C.J., Cheng K.W., Chen C.L., et al. Predictive factors for pediatric patients requiring massive blood transfusion during living donor liver transplantation. Ann Transplant. 2013; 18: 443–7.
24. Cywinski J.B., Alster J.M., Miller C., et al. Prediction of intraoperative transfusion requirements during orthotopic liver transplantation and the influence on postoperative patient survival. Anesth Analg. 2014; 118: 428–37.
25. Mitra B., O’Reilly G., Collecutt M., et al. Prospective comparison of pointof-care international normalised ratio measurement versus plasma international normalised ratio for acute traumatic coagulopathy. Emerg Med Australas. 2012; 24: 363–8.
26. Gozal Y. Point-of-care testing in the acute management of mild traumatic brain injury: Identifying the coagulopathic patient. Neurocrit Care. 2014; 21: S141.
27. Reinhofer M., Brauer M., Franke U., et al. The value of rotation thromboelastometry to monitor disturbed perioperative haemostasis and bleeding risk in patients with cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2008; 19: 212–9.
28. Haas T., Spielmann N., Mauch J., et al. Correlation of activated clotting times and standard laboratory coagulation tests in paediatric noncardiac surgery. Scand J Clin Lab Invest. 2013; 73: 29–33.
29. Wikkelsoe A.J., Afshari A., Wetterslev J., et al. Monitoring patients at risk of massive transfusion with thrombelastography or thromboelastometry: A systematic review. Acta Anaesthesiol Scand. 2011; 55: 1174–89.
30. Harvey H. Thromboelastography reveals abnormalities not detected by standard coagulation studies after pediatric traumatic brain injury. Pediatr Crit Care Med. 2014; 15: 75–6.
31. Theusinger O.M., Baulig W., Seifert B., et al. Changes in coagulation in standard laboratory tests and ROTEM in trauma patients between onscene and arrival in the emergency department. Anesth Analg. 2015; 120: 627–35.
32. Schaden E., Kimberger O., Kraincuk P., et al. Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. Br J Anaesth. 2012; 109: 376–81.
33. Hunt H., Stanworth S, Curry N., et al. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst Rev. 2015; (2): CD010438.
34. Quinn M., Drummond R.J., Ross F., et al. Short course preoperative ferrous sulphate supplementation — is it worthwhile in patients with colorectal cancer? Ann R Coll Surg Engl. 2010; 92: 569–72.
35. De Candia E., Bocci M.G., Caricato A., et al. Viscoelastic versus standard coagulation tests in the management of acute trauma. Thromb Res. 2014; 134: S70–1.
36. Ak K., Isbir C.S., Tetik S., et al. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: A prospective randomized study. J Card Surg. 2009; 24: 404–10.
37. Avidan M.S., Alcock E.L., Da Fonseca J., et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth. 2004; 92: 178–86.
38. Cui Y, Hei F, Long C, et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artif Organs. 2010; 34: 955–60.
39. Girdauskas E., Kempfert J., Kuntze T., et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: A prospective, randomized trial. J Thorac Cardiovasc Surg. 2010; 140: 1117. e2–1124.e2.
40. Kultufan Turan S., Aydinli B., Ayik H., et al. The role of rotational thromboelastgraphy on decision of blood transfusion in open heart surgery. GKD Anest Yog Bak Dern Derg. 2006; 12: 154–9.
41. Nakayama Y., Nakajima Y., Tanaka K.A., et al. Thromboelastometry-guided intraoperative haemostatic management reduces bleeding and red cell transfusion after paediatric cardiac surgery. Br J Anaesth. 2015; 114: 91–102.
42. Nuttall G.A., Oliver W.C., Santrach P.J., et al. Effi cacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology. 2001; 94: 773–81.
43. Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase-modifi ed thrombelastography during cardiopulmonary bypass. Br J Anaesth. 2001; 86: 575–8.
44. Shore-Lesserson L., Manspeizer H.E., DePerio M., et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999; 88: 312–9.
45. Weber C.F., Gorlinger K., Meininger D., et al. Point-of-care testing: A prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012; 117: 531–47.
46. Westbrook A.J., Olsen J., Bailey M., et al. Protocol based on thromboelastograph (TEG) out-performs physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery: A pilot study. Heart Lung Circ. 2009; 18: 277–88.
47. Afshari A., Wikkelso A., Brok J., et al. Thrombelastography, (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev. 2011; (3): CD007871.
48. Bolliger D., Tanaka K.A. Roles of thrombelastography and thromboelastometry for patient blood management in cardiac surgery. Transfus Med Rev. 2013; 27: 213–20.
49. Chowdhury M., Shore-Lesserson L., Mais A.M., Leyvi G. Thromboelastograph with Platelet Mapping(TM) predicts postoperative chest tube drainage in patients undergoing coronary artery bypass grafting. J Cardiothorac Vasc Anesth. 2014; 28: 217–23.
50. Yang L., Vuylsteke A., Gerrard C., et al. Postoperative fibrinogen level is associated with postoperative bleeding following cardiothoracic surgery and the effect of fibrinogen replacement therapy remains uncertain. J Thromb Haemost. 2013; 11: 1519–26.
51. Faraoni D., Willems A., Savan V., et al. Plasma fibrinogen concentration is correlated with postoperative blood loss in children undergoing cardiac surgery. A retrospective review. Eur J Anaesthesiol. 2014; 31: 317–26.
52. Pekelharing J., Furck A., Banya W., et al. Comparison between thromboelastography and conventional coagulation tests after cardiopulmonary bypass surgery in the paediatric intensive care unit. Int J Lab Hematol. 2014; 36: 465–71.
53. Sharma A.D., Al-Achi A., Seccombe J.F., et al. Does incorporation of thromboelastography improve bleeding prediction following adult cardiac surgery? Blood Coagul Fibrinolysis. 2014; 25: 561–70.
54. Allingstrup M., Wetterslev J., Ravn F.B., et al. Antithrombin III for critically ill patients: A systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2016; 42: 505–20.
55. Allingstrup M., Wetterslev J., Ravn F.B., et al. Antithrombin III for critically ill patients. Cochrane Database Syst Rev. 2016; (2): CD005370.
56. Beattie G.W., Jeffrey R.R. Is there evidence that fresh frozen plasma is superior to antithrombin administration to treat heparin resistance in cardiac surgery? Interact Cardiovasc Thorac Surg. 2014; 18: 117–20.
57. Quintero J., Ortega J., Miserachs M., et al. Low plasma levels of antithrombin III in the early postoperative period following pediatric liver transplantation: Should they be replaced? A single center pilot study. Pediatr Transplant. 2014; 18: 185–9.
58. Vinholt P.J., Hvas A.M., Nybo M. An overview of platelet indices and methods for evaluating platelet function in thrombocytopenic patients. Eur J Haematol. 2014; 92: 367–76.
59. Brophy G.M., Contaifer D., Mohammed B.M., et al. Multimodality monitoring of platelet function in traumatic brain injury patients with trauma induced coagulopathy. J Neurotrauma. 2014; 31: A-19.
60. Gurbel P.A., Jeong Y.-H., Mahla E., et al. The association of preoperative platelet function testing and bleeding patients undergoing elective coronary artery bypass grafting. J Am Coll Cardiol. 2012; 59: E1455.
61. Orlov D., McCluskey S.A., Selby R., et al. Platelet dysfunction as measured by a point-of-care monitor is an independent predictor of high blood loss in cardiac surgery. Anesth Analg. 2014; 118: 257–63.
62. Schimmer C., Hamouda K., Sommer S.P., et al. The predictive value of multiple electrode platelet aggregometry (multiplate) in adult cardiac surgery. Thorac Cardiovasc Surg. 2013; 61: 733–43.
63. Corredor C., Wasowicz M., Karkouti K., Sharma V. The role of point-ofcare platelet function testing in predicting postoperative bleeding following cardiac surgery: A systematic review and meta-analysis. Anaesthesia. 2015; 70: 715–31.
64. Mahla E., Tantry U.S., Gurbel P.A. Platelet function testing before CABG is recommended in the guidelines: but do we have enough evidence? J Interv Cardiol. 2015; 28: 233–5.
65. Aradi D., Storey R.F., Komocsi A., et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014; 35: 209–15.
66. Berger P.B., Kirchner H.L., Wagner E.S., et al. Does preoperative platelet function predict bleeding in patients undergoing off pump coronary artery bypass surgery? J Interv Cardiol. 2015; 28: 223–32.
67. Gandhi C.D., Bulsara K.R., Fifi J., et al. Platelet function inhibitors and platelet function testing in neurointerventional procedures. J Neurointerv Surg. 2014; 6: 567–77.
68. Daly M.E., Leo V.C., Lowe G.C., et al. What is the role of genetic testing in the investigation of patients with suspected platelet function disorders? Br J Haematol. 2014; 165: 193–203.
69. Dovlatova N., Lordkipanidze M., Lowe G.C., et al. Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders. J Thromb Haemost. 2014; 12: 660–5.
70. Watson S.P., Lowe G.C., Lordkipanidze M., Morgan N.V., the GAPP Consortium. Genotyping and phenotyping of platelet function disorders. J Thromb Haemost. 2013; 11(Suppl 1): 351–63.
71. Leo V.C., Morgan N.V., Bem D., et al. Use of next-generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders. J Thromb Haemost. 2015; 13: 643–50.
72. Arora P., Kolli H., Nainani N., et al. Preventable risk factors for acute kidney injury in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 2012; 26: 687–97.
73. Schiergens T.S., Rentsch M., Kasparek M.S., et al. Impact of perioperative allogeneic red blood cell transfusion on recurrence and overall survival after resection of colorectal liver metastases. Dis Colon Rectum. 2015; 58: 74–82.
74. Steinbicker A., Zurheiden N.J., Buckmann A., et al. Patient blood management: Umsetzung im Rahmen der Anaesthesiesprechstunde. Anaesth Intensivmed. 2015; 56: 64–74.
75. Bisbe E., Molto L., Arroyo R., et al. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty. Br J Anaesth. 2014; 113: 402–9.
76. Gillard S., Van Aelbrouck C., El Kenz H., et al. Influence of haematocrit level on thromboelastometry parameters: 6AP5-10. Eur J Anaesthesiol. 2014; 31: 106.
77. Solomon C., Rahe-Meyer N., Schochl H., et al. Effect of haematocrit on fibrinbased clot firmness in the FIBTEM test. Blood Transfus. 2013; 11: 412–8.
78. Allen C.J., Tashiro J., Valle E.J., et al. Initial hematocrit predicts the use of blood transfusion in the pediatric trauma patient. J Pediatr Surg. 2014; 49: 1678–82.
79. Baumann H., Chavez V.V., Biscoping J., Schlegel E. Preoperative hemoglobin level, blood volume or circulating red blood cell volume as predictors for perioperative blood transfusion? A retrospective study on 681 patients undergoing orthopedic major joint replacement. Eur J Anaesthesiol. 2014; 31(Suppl 52): 90.
80. Browning R.M., Trentino K., Nathan E.A., Hashemi N. Preoperative anaemia is common in patients undergoing major gynaecological surgery and is associated with a fivefold increased risk of transfusion. Aust N Z J Obstet Gynaecol. 2012; 52: 455–9.
81. David O., Sinha R., Robinson K., Cardone D. The prevalence of anaemia, hypochromia and microcytosis in preoperative cardiac surgical patients. Anaesth Intensive Care. 2013; 41: 316–21.
82. Theusinger O.M., Kind S.L., Seifert B., et al. Patient blood management in orthopaedic surgery: A four-year follow-up of transfusion requirements and blood loss from 2008 to 2011 at the Balgrist University Hospital in Zurich, Switzerland. Blood Transfus. 2014; 12: 195–203.
83. Enko D., Wallner F., von-Goedecke A., et al. The impact of an algorithmguided management of preoperative anemia in perioperative hemoglobin level and transfusion of major orthopedic surgery patients. Anemia. 2013; 2013: 641876.
84. Harwin S.F., Pivec R., Naziri Q., et al. Is total hip arthroplasty a successful and safe procedure in Jehovah’s Witnesses? Mean five-year results. Hip Int. 2014; 24: 69–76.
85. Qureshi M., Momoh I., Bankes M., et al. Erythropoietin provides a useful strategy for treating preoperative anemia in planned elective orthopedic surgery: An analysis of benefit in routine practice. Transfusion. 2012; 52: 2063–4.
86. Bisbe E., Munoz M. Management of preoperative anemia: The NATA consensus statements. ISBT Sci Ser. 2012; 7: 283–7.
87. Bruce W., Campbell D., Daly D., Isbister J. Practical recommendations for patient blood management and the reduction of perioperative transfusion in joint replacement surgery. ANZ J Surg. 2013; 83: 222–9.
88. Gurusamy K.S., Nagendran M., Broadhurst J.F., et al. Iron therapy in anaemic adults without chronic kidney disease. Cochrane Database Syst Rev. 2014; (12): CD010640.
89. Lakkawar N.J., Sankaran S., Rangaswamy T. Efficacy of intravenous administration of iron sucrose for treatment of iron deficiency anaemia in patients with abnormal uterine bleeding. Acta Facultatis Medicae Naissensis. 2012; 29: 59–68.
90. Keeler B.D., Simpson J.A., Ng S., et al. The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer. Colorectal Dis. 2014; 16: 794–800.
91. Lin D.M., Lin E.S., Tran M.H. Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: A systematic review. Transfus Med Rev. 2013; 27: 221–34.
92. Alsaleh K., Alotaibi G.S., Almodaimegh H.S., et al. The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty: A meta-analysis of randomized clinical trials. J Arthroplasty. 2013; 28: 1463–72.
93. Doodeman H.J., van Haelst I.M., Egberts T.C., et al. The effect of a preoperative erythropoietin protocol as part of a multifaceted blood management program in daily clinical practice (CME). Transfusion. 2013; 53: 1930–9.
94. van Haelst I.M., Egberts A.C., Doodeman H.J., et al. Occurrence and determinants of poor response to short-term preoperative erythropoietin treatment. Acta Anaesthesiol Scand. 2013; 57: 350–7.
95. Tomeczkowski J., Stern S., Muller A., von Heymann C. Potential cost saving of Epoetin alfa in elective hip or knee surgery due to reduction in blood transfusions and their side effects: A discrete-event simulation model. PLoS ONE. 2013; 8: e72949.
96. Kotze A., Carter L.A., Scally A.J. Effect of a patient blood management programme on preoperative anaemia, transfusion rate, and outcome after primary hip or knee arthroplasty: A quality improvement cycle. Br J Anaesth. 2012; 108: 943–52.
97. Cladellas M., Farre N., Comin-Colet J., et al. Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement. Am J Cardiol. 2012; 110: 1021–6.
98. Menkis A.H., Martin J., Cheng D.C., et al. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: A consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. Innovations (Phila). 2012; 7: 229–41.
99. Leahy M.F., Roberts H., Mukhtar S.A., et al. A pragmatic approach to embedding patient blood management in a tertiary hospital. Transfusion. 2014; 54: 1133–45.
100. Munoz M., Gomez-Ramirez S., Martin-Montanez E., et al. Cost of postoperative intravenous iron therapy in total lower limb arthroplasty: A retrospective, matched cohort study. Blood Transfus. 2014; 12: 40–9.
101. Crosby L., Palarski V.A., Cottington E., Cmolik B. Iron supplementation for acute blood loss anemia after coronary artery bypass surgery: A randomized, placebo-controlled study. Heart Lung. 1994; 23: 493–9.
102. Garrido-Martin P., Nassar-Mansur M.I., de la Llana-Ducros R., et al. The effect of intravenous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: A randomized clinical trial. Interact Cardiovasc Thorac Surg. 2012; 15: 1013–8.
103. Karkouti K., McCluskey S.A., Ghannam M., et al. Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia. Can J Anaesth. 2006; 53: 11–9.
104. Madi-Jebara S.N., Sleilaty G.S., Achouh P.E., et al. Postoperative intravenous iron used alone or in combination with low-dose erythropoietin is not effective for correction of anemia after cardiac surgery. J Cardiothorac Vasc Anesth. 2004; 18: 59–63.
105. Parker M.J. Iron supplementation for anemia after hip fracture surgery: A randomized trial of 300 patients. J Bone Joint Surg Am. 2010; 92: 265–9.
106. Mundy G.M., Birtwistle S.J., Power R.A. The effect of iron supplementation on the level of haemoglobin after lower limb arthroplasty. J Bone Joint Surg Br. 2005; 87: 213–7.
107. Sutton A.G., Campbell P.G., Graham R., et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: The Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol. 2004; 44: 287–96.
108. Zauber N.P., Zauber A.G., Gordon F.J., et al. Iron supplementation after femoral head replacement for patients with normal iron stores. JAMA. 1992; 267: 525–7.
109. Titos-Arcos J.C., Soria-Aledo V., Carrillo-Alcaraz A., et al. Is intravenous iron useful for reducing transfusions in surgically treated colorectal cancer patients? World J Surg. 2012; 36: 1893–7.
110. van Iperen C.E., Kraaijenhagen R.J., Biesma D.H., et al. Iron metabolism and erythropoiesis after surgery. Br J Surg. 1998; 85: 41–5.
111. Abuella G., Corredor C., Arulkumaran N., et al. Meta-analysis of goal directed therapy in high-risk patients undergoing major noncardiac surgery. Intensive Care Med. 2012; 38: S120.
112. Benes J., Giglio M., Brienza N., Michard F. The effects of goal-directed fluid therapy based on dynamic parameters on postsurgical outcome: A metaanalysis of randomized controlled trials. Crit Care. 2014; 18: 584. 1
113. Cecconi M., Corredor C., Arulkumaran N., et al. Clinical review: Goaldirected therapy — what is the evidence in surgical patients? The effect on different risk groups. Crit Care. 2013; 17: 209.
114. Aya H.D., Cecconi M., Hamilton M., Rhodes A. Goal-directed therapy in cardiac surgery: A systematic review and meta-analysis. Br J Anaesth. 2013; 110: 510–7.
115. Grocott M.P., Dushianthan A., Hamilton M.A., et al. Perioperative increase in global blood flow to explicit defined goals and outcomes after surgery: A Cochrane Systematic Review. Br J Anaesth. 2013; 111: 535–48.
116. Salzwedel C., Puig J., Carstens A., et al. Perioperative goal-directed hemodynamic therapy based on radial arterial pulse pressure variation and continuous cardiac index trending reduces postoperative complications after major abdominal surgery: A multicenter, prospective, randomized study. Crit Care. 2013; 17: R191.
117. Pearse R.M., Harrison D.A., MacDonald N., et al. Effect of a perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: A randomized clinical trial and systematic review. JAMA. 2014; 311: 2181–90.
118. Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth. 1997; 78: 606–17.
119. Cuthbertson B.H. Goldilocks, elephants, and surgical fluids. Br J Anaesth. 2013; 110: 144–5.
120. Vaughan-Shaw P.G., Saunders J., Smith T., et al. Oedema is associated with clinical outcome following emergency abdominal surgery. Ann R Coll Surg Engl. 2013; 95: 390–6.
121. Marik P.E., Cavallazzi R. Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. Crit Care Med. 2013; 41: 1774–81.
122. Cannesson M., Le Manach Y., Hofer C.K., et al. Assessing the diagnostic accuracy of pulse pressure variations for the prediction of fluid responsiveness: A ‘gray zone’ approach. Anesthesiology. 2011; 115: 231–41.
123. Sondergaard S. Pavane for a pulse pressure variation defunct. Crit Care. 2013; 17: 327.
124. Marik P.E., Lemson J. Fluid responsiveness: An evolution of our understanding. Br J Anaesth. 2014; 112: 617–20.
125. Murphy G.J., Pike K., Rogers C.A., et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med. 2015; 372: 997–1008.
126. Villanueva C., Colomo A., Bosch A., et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013; 368: 11–21.
127. de Almeida J.P., Vincent J.L., Galas F.R., et al. Transfusion requirements in surgical oncology patients: A prospective, randomized controlled trial. Anesthesiology. 2015; 122: 29–38.
128. Rohde J.M., Dimcheff D.E., Blumberg N., et al. Healthcare-associated infection after red blood cell transfusion: A systematic review and metaanalysis. JAMA. 2014; 311: 1317–26.
129. Cabello J.B., Burls A., Emparanza J.I., et al. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev. 2013; (8): CD007160.
130. Wetterslev J., Meyhoff C.S., Jorgensen L.N., et al. The effects of high perioperative inspiratory oxygen fraction for adult surgical patients. Cochrane Database Syst Rev. 2015; (6): CD008884.
131. Andreu G., Morel P., Forestier F., et al. Hemovigilance network in France: Organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion. 2002; 42: 1356–64.
132. Chung K.W., Harvey A., Basavaraju S.V., Kuehnert M.J. How is national recipient hemovigilance conducted in the United States? Transfusion. 2015; 55: 703–7.
133. Faber J.C. The European Blood Directive: A new era of blood regulation has begun. Transfus Med. 2004; 14: 257–73.
134. Watson R. EU tightens rules on blood safety. BMJ. 2005; 331: 800.
135. de Vries RR, Faber J.C., Strengers P.F.; Board of the International Haemovigilance Network. Haemovigilance: An effective tool for improving transfusion practice. Vox Sang. 2011; 100: 60–7.
136. Giampaolo A., Piccinini V., Catalano L., et al. The first data from the haemovigilance system in Italy. Blood Transfus. 2007; 5: 66–74.
137. Keller-Stanislawski B., Lohmann A., Gunay S., et al. The German Haemovigilance System: Reports of serious adverse transfusion reactions between 1997 and 2007. Transfus Med. 2009; 19: 340–9.
138. Bolton-Maggs P.H., Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol. 2013; 163: 303–14.
139. Lafeuillade B., Eb F., Ounnoughene N., et al. Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000 to 2008. Transfusion. 2015; 55: 636–46.
140. Custer B., Kessler D., Vahidnia F., et al. Risk factors for retrovirus and hepatitis virus infections in accepted blood donors. Transfusion. 2015; 55: 1098–1107.
141. Stramer S.L., Notari E.P., Krysztof D.E., Dodd R.Y. Hepatitis B virus testing by minipool nucleic acid testing: Does it improve blood safety? Transfusion. 2013; 53: 2449–58.
142. Bruhn R., Lelie N., Busch M., Kleinman S.; International NAT Study Group. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions. Transfusion. 2015; 55: 1195–1205.
143. Zou S., Dorsey K.A., Notari E.P., et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010; 50: 1495–1504.
144. Arora S., Doda V., Kirtania T. Sensitivity of individual donor nucleic acid testing (NAT) for the detection of hepatitis B infection by studying diluted NAT yield samples. Blood Transfus. 2015; 13: 227–32.
145. Stramer S.L. Current perspectives in transfusion-transmitted infectious diseases: Emerging and re-emerging infections. ISBT Sci Ser. 2014; 9: 30–6.
146. Seltsam A., Muller T.H. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol. 2013; 162: 442–54.
147. Rock G. A comparison of methods of pathogen inactivation of FFP. Vox Sang. 2011; 100: 169–78.
148. Butler C., Doree C., Estcourt L.J., et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev. 2013; (3): CD009072.
149. Wagner S.J. Developing pathogen reduction technologies for RBC suspensions. Vox Sang. 2011; 100: 112–21.
150. Kleinman S., Stassinopoulos A. Risks associated with red blood cell transfusions: Potential benefits from application of pathogen inactivation. Transfusion. 2015; 55: 2983–3000.
151. Gilliss B.M., Looney M.R., Gropper M.A. Reducing noninfectious risks of blood transfusion. Anesthesiology. 2011; 115: 635–49.
152. Edgeworth J.A., Farmer M., Sicilia A., et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: A blood-based assay. Lancet. 2011; 377: 487–93.
153. Lescoutra-Etchegaray N., Sumian C., Culeux A., et al. Removal of exogenous prion infectivity in leukoreduced red blood cells unit by a specific filter designed for human transfusion. Transfusion. 2014; 54: 1037–45.
154. Bilgin Y.M., van de Watering L.M., Eijsman L., et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation. 2004; 109: 2755– 60.
155. Mendrone A. Jr., Fabron A. Jr., Langhi D. Jr., et al. Is there justification for universal leukoreduction? Rev Bras Hematol Hemoter. 2014; 36: 237.
156. Douet J.Y., Bujdoso R., Andreoletti O. Leukoreduction and blood-borne vCJD transmission risk. Curr Opin Hematol. 2015; 22: 36–40.
157. Carson J.L., Carless P.A., Hebert P.C. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012; (4): CD002042.
158. Holst L.B., Petersen M.W., Haase N., et al. Restrictive versus liberal transfusion strategy for red blood cell transfusion: Systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ. 2015; 350: h1354.
159. Holst L.B., Haase N., Wetterslev J., et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014; 371: 1381–91.
160. Curley G.F., Shehata N., Mazer C.D., et al. Transfusion triggers for guiding RBC transfusion for cardiovascular surgery: A systematic review and meta-analysis. Crit Care Med. 2014; 42: 2611–24.
161. Murphy G.J., Pike K., Rogers C.A., et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med. 2015; 372: 997–1008.
162. Bolton Maggs P.H.B., Poles D., et al., on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2014 annual SHOT report (2015). 2015; 1–197.
163. Bolton-Maggs P.H. Transfusion safety in 2012: main messages from the SHOT Annual Report for 2012. Transfus Med. 2013; 23: 217–8.
164. Ozier Y., Muller J.Y., Mertes P.M., et al. Transfusion-related acute lung injury: Reports to the French Hemovigilance Network 2007 through 2008. Transfusion. 2011; 51: 2102–10.
165. Muller M.C., van Stein D., Binnekade J.M., et al. Low-risk transfusion-related acute lung injury donor strategies and the impact on the onset of transfusion-related acute lung injury: A meta-analysis. Transfusion. 2015; 55: 164–75.
166. Kopolovic I., Ostro J., Tsubota H., et al. A systematic review of transfusionassociated graft-versus-host disease. Blood. 2015; 126: 406–14.
167. Bolton Maggs P.H.B., Poles D., Watt A., et al., on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2012 Annual SHOT Report (2013). 2013; 1–200.
168. Clifford L., Jia Q., Yadav H., et al. Characterizing the epidemiology of perioperative transfusion-associated circulatory overload. Anesthesiology. 2015; 122: 21–8.
169. Piccin A., Cronin M., Brady R., et al. Transfusion-associated circulatory overload in Ireland: A review of cases reported to the National Haemovigilance Office 2000 to 2010. Transfusion. 2015; 55: 1223–30.
170. Alam A., Lin Y., Lima A., et al. The prevention of transfusion-associated circulatory overload. Transfus Med Rev. 2013; 27: 105–12.
171. Ozier Y. The prevention of transfusion-associated circulatory overload. Transfus Clin Biol. 2014; 21: 153–7.
172. Murphy E.L., Kwaan N., Looney M.R., et al. Risk factors and outcomes in transfusion-associated circulatory overload. Am J Med. 2013; 126: 357. e29–357.e38.
173. Vamvakas E.C. Meta-analysis of clinical studies of the purported deleterious effects of ‘old’ (versus ‘fresh’) red blood cells: Are we at equipoise? Transfusion. 2010; 50: 600–10.
174. Lelubre C., Vincent J.L. Relationship between red cell storage duration and outcomes in adults receiving red cell transfusions: A systematic review. Crit Care. 2013; 17: R66.
175. Wang D., Sun J., Solomon S.B., et al. Transfusion of older stored blood and risk of death: A meta-analysis. Transfusion. 2012; 52: 1184–95.
176. Fergusson D.A., Hebert P., Hogan D.L., et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: The ARIPI randomized trial. JAMA. 2012; 308: 1443–51.
177. Lacroix J., Hebert P.C., Fergusson D.A., et al. Age of transfused blood in critically ill adults. N Engl J Med. 2015; 372: 1410–8.
178. Steiner M.E., Ness P.M., Assmann S.F., et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med. 2015; 372: 1419–29.
179. Carless P.A., Henry D.A., Moxey A.J., et al. Cell salvage for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2010; (4): CD001888.
180. van Bodegom-Vos L., Voorn V.M., So-Osman C., et al. Cell salvage in hip and knee arthroplasty: A meta-analysis of randomized controlled trials. J Bone Joint Surg Am. 2015; 97: 1012–21.
181. Xie J., Feng X., Ma J., et al. Is postoperative cell salvage necessary in total hip or knee replacement? A meta-analysis of randomized controlled trials. Int J Surg. 2015; 21: 135–44.
182. Shantikumar S., Patel S., Handa A. The role of cell salvage autotransfusion in abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg. 2011; 42: 577–84.
183. Esper S.A., Waters J.H. Intra-operative cell salvage: A fresh look at the indications and contraindications. Blood Transfus. 2011; 9: 139–47.
184. Li J., Sun S.L., Tian J.H., et al. Cell salvage in emergency trauma surgery. Cochrane Database Syst Rev. 2015; (1): CD007379.
185. Trudeau J.D., Waters T., Chipperfi eld K. Should intraoperative cell-salvaged blood be used in patients with suspected or known malignancy? Can J Anaesth. 2012; 59: 1058–70.
186. Aning J., Dunn J., Daugherty M., et al. Towards bloodless cystectomy: A 10- year experience of intra-operative cell salvage during radical cystectomy. BJU Int. 2012; 110: E608–13.
187. Raval J.S., Nelson J.B., Woldemichael E., Triulzi D.J. Intraoperative cell salvage in radical prostatectomy does not appear to increase long-term biochemical recurrence, metastases, or mortality. Transfusion. 2012; 52: 2590–3.
188. Gakhar H., Bagouri M., Bommireddy R., Klezl Z. Role of intraoperative red cell salvage and autologus transfusion in metastatic spine surgery: A pilot study and review of literature. Asian Spine J. 2013; 7: 167–72.
189. Bowley D.M., Barker P., Boffard K.D. Intraoperative blood salvage in penetrating abdominal trauma: A randomised, controlled trial. World J Surg. 2006; 30: 1074–80.
190. Liumbruno G.M., Liumbruno C., Rafanelli D. Intraoperative cell salvage in obstetrics: Is it a real therapeutic option? Transfusion. 2011; 51: 2244– 56.
191. Dhariwal S.K., Khan K.S., Allard S., et al. Does current evidence support the use of intraoperative cell salvage in reducing the need for blood transfusion in caesarean section? Curr Opin Obstet Gynecol. 2014; 26: 425–30.
192. De Pietri L., Bianchini M., Montalti R., et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy. A randomized controlled trial. Hepatology. 2016; 63: 566–73.
193. Berg K., Langaas M., Ericsson M., et al. Acetylsalicylic acid treatment until surgery reduces oxidative stress and inflammation in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg. 2013; 43: 1154–63.
194. Xiao F., Wu H., Sun H., et al. Effect of preoperatively continued aspirin use on early and mid-term outcomes in off-pump coronary bypass surgery: A propensity score-matched study of 1418 patients. PLoS ONE. 2015; 10: e0116311.
195. Vorobcsuk A., Aradi D., Farkasfalvi K., et al. Outcomes of patients receiving clopidogrel prior to cardiac surgery. Int J Cardiol. 2012; 156: 34–40.
196. Blais D.M., Zukkoor S.M., Hayes C., et al. Bleeding outcomes associated with coronary artery bypass graft surgery and recent clopidogrel exposure. Heart Surgery Forum. 2012; 16: E70–7.
197. Guay J., Andrew Ochroch E. Continuing antiplatelet therapy before cardiac surgery with cardiopulmonary bypass: A meta-analysis on the need for reexploration and major outcomes. J Cardiothorac Vasc Anesth. 2014; 28: 90–7.
198. Rossini R, Musumeci G., Capodanno D., et al. Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. Thromb Haemost. 2015; 113: 272–82.
199. Hutton B., Joseph L., Fergusson D., et al. Risks of harms using antifibrinolytics in cardiac surgery: Systematic review and network metaanalysis of randomised and observational studies. BMJ. 2012; 345: e5798.
200. Meybohm P., Herrmann E., Nierhoff J., Zacharowski K. Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and (epsilon)- aminocaproic acid: A metaanalysis of randomised and observational trials of over 30,000 patients. PLoS ONE. 2013; 8: e58009.
201. Ranucci M., Baryshnikova E., Crapelli G.B., et al. Preoperative antithrombin supplementation in cardiac surgery: A randomized controlled trial. J Thorac Cardiovasc Surg. 2013; 145: 1393–9.
202. Ranucci M., Jeppsson A., Baryshnikova E. Preoperative fibrinogen supplementation in cardiac surgery patients: An evaluation of different trigger values. Acta Anaesthesiol Scand. 2015; 59: 427–33.
203. Vonk A.B., Veerhoek D., van den Brom C.E., et al. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth. 2014; 28: 235–41.
204. Guo Y., Tang J., Du L., et al. Protamine dosage based on two titrations reduces blood loss after valve replacement surgery: A prospective, double-blinded, randomized study. Can J Cardiol. 2012; 28: 547–52.
205. Martin K., Gertler R., MacGuill M., et al. Replacement of aprotinin by epsilonaminocaproic acid in infants undergoing cardiac surgery: Consequences for blood loss and outcome. Br J Anaesth. 2013; 110: 615–21.
206. Makhija N., Sarupria A., Kumar Choudhary S., et al. Comparison of epsilon aminocaproic acid and tranexamic acid in thoracic aortic surgery: Clinical efficacy and safety. J Cardiothorac Vasc Anesth. 2013; 27: 1201–7.
207. Faraoni D., Willems A., Melot C., et al. Efficacy of tranexamic acid in paediatric cardiac surgery: A systematic review and meta-analysis. Eur J Cardiothorac Surg. 2012; 42: 781–6.
208. Mansouri M., Attary M., Bagheri K., et al. Comparative evaluation of the effects of tranexamic acid and low-dose aprotinin on postvalvular heart surgery bleeding and allogenic transfusion. Interact Cardiovasc Thorac Surg. 2012; 15: 23–7.
209. Waldow T., Szlapka M., Haferkorn M., et al. Prospective clinical trial on dosage optimizing of tranexamic acid in nonemergency cardiac surgery procedures. Clin Hemorheol Microcirc. 2013; 55: 457–68.
210. Du Y., Xu J., Wang G., et al. Comparison of two tranexamic acid dose regimens in patients undergoing cardiac valve surgery. J Cardiothorac Vasc Anesth. 2014; 28: 1233–7.
211. Sigaut S., Tremey B., Ouattara A., et al. Comparison of two doses of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Anesthesiology. 2014; 120: 590–600.
212. Faraoni D., Cacheux C., Van Aelbrouck C., et al. Effect of two doses of tranexamic acid on fibrinolysis evaluated by thromboelastography during cardiac surgery: A randomised, controlled study. Eur J Anaesthesiol. 2014; 31: 491–8.
213. Vanek T., Straka Z. Topical use of tranexamic acid in cardiac surgery — a review and meta-analysis of four randomized controlled trials. Cor Vasa. 2013; 55: e184–9.
214. Hosseini H., Rahimianfar A.A., Abdollahi M.H., et al. Evaluations of topical application of tranexamic acid on postoperative blood loss in off-pump coronary artery bypass surgery. Saudi J Anaesth. 2014; 8: 224–8.
215. Mahaffey R., Wang L., Hamilton A., et al. Aretrospective analysis of blood loss with combined topical and intravenous tranexamic acid after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2013; 27: 18–22.
216. Wang G., Xie G., Jiang T., et al. Tranexamic acid reduces blood loss after off-pump coronary surgery: A prospective, randomized, double-blind, placebocontrolled study. Anesth Analg. 2012; 115: 239–43.
217. Gurian D.B., Meneghini A., de Abreu L.C., et al. A randomized trial of the topical effect of antifibrinolytic epsilon aminocaproic acid on coronary artery bypass surgery without cardiopulmonary bypass. Clin Appl Thromb Hemost. 2014; 20: 615–20.
218. Lee S.H., Lee S.M., Kim C.S., et al. Fibrinogen recovery and changes in fibrinbased clot firmness after cryoprecipitate administration in patients undergoing aortic surgery involving deep hypothermic circulatory arrest. Transfusion. 2014; 54: 1379–87.
219. Doussau A., Perez P., Puntous M., et al. Fresh-frozen plasma transfusion did not reduce 30-day mortality in patients undergoing cardiopulmonary bypass cardiac surgery with excessive bleeding: The PLASMACARD multicenter cohort study. Transfusion. 2014; 54: 1114–24.
220. Zhou S.F., Estrera A.L., Miller C.C. 3rd, et al. Analysis of autologous plateletrich plasma during ascending and transverse aortic arch surgery. Ann Thorac Surg. 2013; 95: 1525–30.
221. Jin L., Ji H.W. Effect of desmopressin on platelet aggregation and blood loss in patients undergoing valvular heart surgery. Chin Med J (Engl). 2015; 128: 644–7.
222. Karkouti K., von Heymann C., Jespersen C.M., et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg. 2013; 146: 927–39.
223. Rahe-Meyer N., Hanke A., Schmidt D.S., et al. Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: Results from a randomized, placebo-controlled trial. J Thorac Cardiovasc Surg. 2013; 145: S178–85.
224. Galas F.R., de Almeida J.P., Fukushima J.T., et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. J Thorac Cardiovasc Surg. 2014; 148: 1647–55.
225. Bilecen S., Peelen L.M., Kalkman C.J., et al. Fibrinogen concentrate therapy in complex cardiac surgery. J Cardiothorac Vasc Anesth. 2013; 27: 12–7.
226. Giorni C., Ricci Z., Iodice F., et al. Use of Confidex to control perioperative bleeding in pediatric heart surgery: Prospective cohort study. Pediatr Cardiol. 2014; 35: 208–14.
227. Song H.K., Tibayan F.A., Kahl E.A., et al. Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery. J Thorac Cardiovasc Surg. 2014; 147: 1036–40.
228. Rao V.K., Lobato R.L., Bartlett B., et al. Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery. J Cardiothorac Vasc Anesth. 2014; 28: 1221–6.
229. Abdel-Meguid M.E. Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery. Saudi J Anaesth. 2013; 7: 301–4.
230. Singh S.P., Chauhan S., Choudhury M., et al. Recombinant activated factor VII in cardiac surgery: Single-center experience. Asian Cardiovasc Thorac Ann. 2014; 22: 148–54.
231. Kurkluoglu M., Engle A.M., Costello J.P., et al. Single center experience on dosing and adverse events of recombinant factor seven use for bleeding after congenital heart surgery. J Saudi Heart Assoc. 2015; 27: 18–22.
232. Alfirevic A., Duncan A., You J., et al. Recombinant factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg. 2014; 98: 618–24.
233. Clark K.B., Kon N.D., Hammon J.W. Jr., et al. Factor IX complex for the treatment of severe bleeding after cardiac surgery. J Cardiovasc Pharmacol. 2013; 62: 67–71.
234. Alizadeh Ghavidel A., Mirmesdagh Y., Samiei N., Gholampour Dehaki M. Haemostatic role of TachoSil surgical patch in cardiac surgery. J Cardiovasc Thorac Res. 2014; 6: 91–5.
235. Agarwal S., Johnson R.I., Shaw M. Preoperative point-of-care platelet function testing in cardiac surgery. J Cardiothorac Vasc Anesth. 2015; 29: 333–41.
236. Whitney G., Daves S., Hughes A., et al. Implementation of a transfusion algorithm to reduce blood product utilization in pediatric cardiac surgery. Paediatr Anaesth. 2013; 23: 639–46.
237. Karkouti K., McCluskey S.A., Callum J., et al. Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: A retrospective cohort study with interrupted time-series analysis. Anesthesiology. 2015; 122: 560–70.
238. Paidas M.J., Hossain N., Shamsi T.S., et al. Haemostasis and thrombosis in obstetrics and gynaecology. Chichester, West Sussex, UK: Wiley- Blackwell; 2011.
239. Bergmann R.L., Richter R., Bergmann K.E., Dudenhausen J.W. Prevalence and risk factors for early postpartum anemia. Eur J Obstet Gynecol Reprod Biol. 2010; 150: 126–31.
240. Chauleur C., Cochery-Nouvellon E., Mercier E., et al. Analysis of the venous thromboembolic risk associated with severe postpartum haemorrhage in the NOHA First cohort. Thromb Haemost. 2008; 100: 773–9.
241. James A.H., Paglia M.J., Gernsheimer T., et al. Blood component therapy in postpartum hemorrhage. Transfusion. 2009; 49: 2430–3.
242. Ehrenthal D.B., Chichester M.L., Cole O.S., Jiang X. Maternal risk factors for peripartum transfusion. J Women’s Health. 2012; 21: 792–7.
243. WHO guidelines for the management of postpartum haemorrhage and retained placenta. 2009. Available from: http://apps.who.int/iris/bitstream/10665/44171/1/9789241598514_eng.pdf.
244. Cooper G.M., McClure J.H. Anaesthesia chapter from saving mothers’ lives; reviewing maternal deaths to make pregnancy safer. Br J Anaesth. 2008; 100: 17–22.
245. Kacmar R.M., Mhyre J.M., Scavone B.M., et al. The use of postpartum hemorrhage protocols in United States Academic Obstetric Anesthesia Units. Anesth Analg. 2014; 119: 906–10.
246. Gutierrez M.C., Goodnough L.T., Druzin M., Butwick A.J. Postpartum hemorrhage treated with a massive transfusion protocol at a tertiary obstetric center: A retrospective study. Int J Obstet Anesth. 2012; 21: 230–5.
247. Era S., Matsunaga S., Matsumura H., et al. Usefulness of shock indicators for determining the need for blood transfusion after massive obstetric hemorrhage. J Obstet Gynaecol Res. 2014; 41: 39–43.
248. Steele H.B., Goetzl L. The practical utility of routine postpartum hemoglobin assessment. Am J Obstet Gynecol. 2014; 210: 576.e1–6.
249. Patterson J.A., Roberts C.L., Bowen J.R., et al. Blood transfusion during pregnancy, birth, and the postnatal period. Obstet Gynecol. 2014; 123: 126–33.
250. So-Osman C., Cicilia J., Brand A., et al. Triggers and appropriateness of red blood cell transfusions in the postpartum patient — a retrospective audit. Vox Sang. 2010; 98: 65–9.
251. Bonnet M.-P., Deneux-Tharaux C., Dupont C., et al. Transfusion practices in postpartum hemorrhage: A population-based study. Acta Obstet Gynecol Scand. 2013; 92: 404–13.
252. Prick B.W., Duvekot J.J., van der More P.E., et al. Cost-effectiveness of red blood cell transfusion vs. nonintervention in women with acute anaemia after postpartum haemorrhage. Vox Sang. 2014; 107: 381–8.
253. Prick B.W., Jansen A.J.G., Steegers E.A.P., et al. Transfusion policy after severe postpartum haemorrhage: A randomised noninferiority trial. BJOG. 2014; 121: 1005–14.
254. Morikawa M., Kuramoto A., Nakayama M., et al. Intraoperative red cell salvage during obstetric surgery in 50 Japanese women. Int J Gynecol Obstet. 2015; 128: 256–9.
255. Brearton C., Bhalla A., Mallaiah S., Barclay P. The economic benefits of cell salvage in obstetric haemorrhage. Int J Obstet Anesth. 2012; 21: 329–33.
256. Froessler B., Cocchiaro C., Saadat-Gilani K., et al. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: A randomized trial. J Matern Fetal Neonatal Med. 2013; 26: 654–9.
257. De Lloyd L., Collins P.W., Kaye A., Collis R.E. Early fibrinogen as a predictor of red cell requirements during postpartum haemorrhage. Int J Obstet Anesth. 2012; 21: S13.
258. Shibata Y., Shigemi D., Ito M., et al. Association between fibrinogen levels and severity of postpartum hemorrhage in singleton vaginal deliveries at a Japanese perinatal center. J Nippon Med Sch. 2014; 81: 94–6.
259. Collins P.W., Lilley G., Bruynseels D., et al. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: A prospective study. Blood. 2014; 124: 1727–36.
260. Precious E.M., Alikhan R., Lilley G., et al. A prospective study to evaluate early Clauss fibrinogen and fibtem as predictors of progression of major obstetric haemorrhage. J Thromb Haemost. 2013; 11(Suppl 2): 425.
261. Peyvandi F., Biguzzi E., Franchi F., et al. Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage. J Thromb Haemost. 2012; 10: 1451–3.
262. Yamada T., Akaishi R., Oda Y., et al. Antenatal fibrinogen concentrations and postpartum haemorrhage. Int J Obstet Anesth. 2014; 23: 365–70.
263. Karlsson O., Henriksson B.-A., Jeppsson A., Hellgren M. Coagulopathies early in postpartum haemorrhage; thromboelastography and haemostatic laboratory analyses. Thromb Res. 2013; 131: S94.
264. Karlsson O., Jeppsson A., Hellgren M. Major obstetric haemorrhage: Monitoring with thromboelastography, laboratory analyses or both? Int J Obstet Anesth. 2014; 23: 10–7.
265. Harrod I.D., Mallaiah S., Barclay P., et al. Evaluation of FIBTEM A5 guided fibrinogen concentrate administration in massive obstetric haemorrhage. Int J Obstet Anesth. 2014; 23: S16.
266. de Lloyd L., Bovington R., Kaye A., et al. Standard haemostatic tests following major obstetric haemorrhage. Int J Obstet Anesth. 2011; 20: 135–41.
267. Ducloy-Bouthors A.S., Pilla C., Bauters A., et al. Point-of-care prothrombin time testing as an early predictor of severe postpartum hemorrhage. Int J Gynaecol Obstet. 2012; 119: S822–3.
268. Erhabor O., Isaac I., Muhammad A., et al. Some hemostatic parameters in women with obstetric hemorrhage in Sokoto, Nigeria. Int J Womens Health. 2013; 5: 285–91.
269. Chevannes C., Harrod I., Bhalla A., et al. Fast rotational thromboelastometry evaluation in major obstetric haemorrhage. Br J Anaesth. 2012; 109: 484.
270. Lilley G.J., Burkett-St. Lawrent D.A., Collins P.W., Collis R.E. A prospective study to evaluate early Clauss fibrinogen and FIBTEM as predictors for major obstetric haemorrhage. Int J Obstet Anesth. 2013; 22: S7.
271. de Lange N.M., Lance M.D., de Groot R., et al. Obstetric hemorrhage and coagulation: An update. Thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage. Obstet Gynecol Surv. 2012; 67: 426–35.
272. de Lange N.M., van Rheenen-Flach L.E., Lance M.D., et al. Peri-partum reference ranges for ROTEM(R) thromboelastometry. Br J Anaesth. 2014; 112: 852–9.
273. Hill J.S., Devenie G., Powell M. Point-of-care testing of coagulation and fibrinolytic status during postpartum haemorrhage: Developing a thrombelastography(R)-guided transfusion algorithm. Anaesth Intensive Care. 2012; 40: 1007–15.
274. Butwick A., Ting V., Atkinson Ralls L., et al. The association between thromboelastographic parameters and total estimated blood loss in patients undergoing elective cesarean delivery. Anesth Analg. 2011; 112: 1041–7.
275. Macafee B., Campbell J.P., Ashpole K., et al. Reference ranges for thromboelastography (TEG1) and traditional coagulation tests in term parturients undergoing caesarean section under spinal anaesthesia. Anaesthesia. 2012; 67: 741–7.
276. Ekelund K., Pinborg A., Bjerrum O.W., Stensballe J. Thromboelastography and aggregometry guided treatment in a patient with idiopathic thrombocytopenic purpura and postpartum hemorrhage. Acta Anaesthesiol Scand. 2013; 57(Suppl 120): 16–7.
277. Susen S., Tournoys A., Duhamel A., et al. Tranexamic acid inhibits fibrinolysisinduced coagulopathy associated with postpartum hemorrhage. J Thromb Haemost. 2013; 11: 221.
278. Aoki N.J., Venardos K., Andrianopoulos N., et al. Use of blood components in major obstetric hemorrhage: Preliminary findings from the Australian and New Zealand massive transfusion registry (ANZ-MTR). Blood. 2014; 124: 1563.
279. Green L., Knight M., Seeney F.M., et al. Transfusion management and haemostatic changes in major obstetric haemorrhage in the UK. Transfus Med. 2014; 24: 25.
280. Pasquier P., Gayat E., Rackelboom T., et al. An observational study of the fresh frozen plasma: Red blood cell ratio in postpartum hemorrhage. Anesth Analg. 2013; 116: 155–61.
281. Teofili L., Bianchi M., Zanfini B.A., et al. Acute lung injury complicating blood transfusion in postpartum hemorrhage: Incidence and risk factors. Mediterr J Hematol Infect Dis. 2014; 6: e2014069.
282. Teofi li L., Bianchi M., Zanfini B.A., et al. Pregnancy-related hypertensive disorders are the major risk factor for TRALI in patients with severe postpartum hemorrhage. Blood. 2013; 122: 1159.
283. Ickx B., Samama C.M. Fibrinogen concentrates for postpartum haemorrhage? Do not miss the most relevant population! Br J Anaesth. 2015; 114: 548–50.
284. Onwuemene O., Green D., Keith L. Postpartum hemorrhage management in 2012: Predicting the future. Int J Gynaecol Obstet. 2012; 119: 3–5.
285. Wikkelso A.J., Edwards H.M., Afshari A., et al. Preemptive treatment with fibrinogen concentrate for postpartum haemorrhage: Randomized controlled trial. Br J Anaesth. 2015; 114: 623–33.
286. Collis R.E., Collins P.W. Haemostatic management of obstetric haemorrhage. Anaesthesia. 2015; 70(Suppl 1): 78–86; e27-8.
287. Cunningham F.G., Nelson D.B. Disseminated intravascular coagulation syndromes in obstetrics. Obstet Gynecol. 2015; 126: 999–1011.
288. Mallaiah S., Barclay P., Harrod I., et al. Significant improvement in the management of major obstetric haemorrhage with a ROTEM guided algorithm using fibrinogen concentrate. Transfus Med. 2014; 24: 7–8.
289. Ahmed S., Byrne B.M. How efficient is fibrinogen concentrate in the management of major obstetric haemorrhage in comparison to cryoprecipitate? Int J Gynaecol Obstet. 2012; 119: S818.
290. Ahmed S., Harrity C., Johnson S., et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage: An observational study. Transfus Med. 2012; 22: 344–9.
291. Wikkelsoe A.J., Afshari A., Stensballe J., et al. The FIB-PPH trial: Fibrinogen concentrate as initial treatment for postpartum haemorrhage: Study protocol for a randomised controlled trial. Trials. 2012; 13: 110.
292. Mallaiah S., Barclay P., Harrod I., et al. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia. 2015; 70: 166–75.
293. Hall D.R. Abruptio placentae and disseminated intravascular coagulopathy. Semin Perinatol. 2009; 33: 189–95.
294. Mirghafourvand M., Mohammad-Alizadeh S., Abbasalizadeh F., Shirdel M. The effect of prophylactic intravenous tranexamic acid on blood loss aftervaginal delivery in women at low risk of postpartum haemorrhage: A double-blind randomised controlled trial. Aust N Z J Obstet Gynaecol. 2015; 55: 53–8.
295. Novikova N., Hofmeyr G.J. Meta-analysis of randomised controlled trials of tranexamic acid for prevention of postpartum haemorrhage. S Afr J Obstet Gynaecol. 2014; 20: 71.
296. Xu J., Gao W., Ju Y. Tranexamic acid for the prevention of postpartum hemorrhage after cesarean section: A double-blind randomization trial. Arch Gynecol Obstet. 2013; 287: 463–8.
297. Bouet P.E., Ruiz V., Madzou S., et al. Policy of tranexamic acid for treating postpartum hemorrhage after a vaginal delivery. Am J Obstet Gynecol. 2014; 210: S302–3.
298. Ducloy-Bouthors A.S., Duhamel A., Jude B., et al. High dose tranexamic acid reduces blood loss in postpartum haemorrhage. Int J Gynaecol Obstet. 2012; 119: S331.
299. Faraoni D., Carlier C., Samama C.M., et al. Efficacy and safety of tranexamic acid administration for the prevention and/or the treatment of postpartum haemorrhage: A systematic review with meta-analysis. Ann Fr Anesth Reanim. 2014; 33: 563–71.
300. Heesen M., Bohmer J., Klohr S., et al. Prophylactic tranexamic acid in patients at low risk for postpartum haemorrhage: Systematic review and meta-analysis. Acta Anaesthesiol Scand. 2014; 58: 1075–85.
301. Walsh M., Ploplis V., Fritz B., et al. Successful thromboelastographic goaldirected blood component therapy, prothrombin complex concentrate, and rFVIIa administration without tranexamic acid for reversal of severe coagulopathy in an obstetrical patient presenting with hemorrhagic cardiac arrest. Am J Hematol. 2014; 89: E50.
302. Kayem G., Kurinczuk J.J., Alfi revic Z., et al. Specific second-line therapies for postpartum haemorrhage: A national cohort study. BJOG. 2011; 118: 856–64.
303. Magon N., Babu K.M., Kapur K., et al. Recombinant activated factor VII in post partum haemorrhage. Niger Med J. 2013; 54: 289–94.
304. Ogawa M., Akahira S., Takahashi S., et al. Low-dose recombinant activated factor VII temporally stopped bleeding from small artery in severe postpartum hemorrhage: A case report. Blood Coagul Fibrinolysis. 2013; 24: 344–6.
305. Quigley J., Byrne J., Diaz M., et al. Use of recombinant factor VIIa (rFVIIa) in acute life threatening primary postpartum haemorrhage: A case report. Vox Sang. 2013; 105: 272–3.
306. Barillari G., Frigo M.G., Casarotto M., et al. Use of recombinant activated factor VII in severe postpartum haemorrhage: Data from the Italian Registry: A multicentric observational retrospective study. Thromb Res. 2009; 124: e41–7.
307. Mostic T., Sparic R., Argirovic R., et al. Our experience with the use of recombinant activated factor VII in postpartum haemorrhage. Srp Arh Celok Lek. 2008; 136(Suppl 3): 204–9.
308. Seidlova D., Blatny J., Penka M., et al. Recombinant activated factor VII in the treatment of life threatening postpartum haemorrhage: Registry UniSeven in the Czech Republic. Ceska Gynekol. 2010; 75: 297–305.
309. Kim S.C., et al. Clinical efficacy of recombinant activated factor VII in postpartum hemorrhage. J Perinat Med. 2013; 41.
310. Lavigne-Lissalde G., Aya G., Mercier F., et al. rhuFVIIa in women with a refractory primary postpartum haemorrhage: An international, multicenter, randomised, opened, controlled trial. Thromb Res. 2013; 131: S74.
311. Fleisher L.A., Fleischmann K.E., Auerbach A.D., et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130: 2215–45.
312. Kristensen S.D., Knuuti J., Saraste A., et al. 2014 ESC/ESA Guidelines on noncardiac surgery: Cardiovascular assessment and management: The Joint Task Force on noncardiac surgery: Cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol. 2014; 31: 517–73.
313. Bidolegui F., Arce G., Lugones A., et al. Tranexamic acid reduces blood loss and transfusion in patients undergoing total knee arthroplasty without tourniquet: A prospective randomized controlled trial. Open Orthop J. 2014; 8: 250–4.
314. Fu D.J., Chen C., Guo L., Yang L. Use of intravenous tranexamic acid in total knee arthroplasty: A meta-analysis of randomized controlled trials. Chin J Traumatol. 2013; 16: 67–76.
315. Gandhi R., Evans H.M., Mahomed S.R., Mahomed N.N. Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: A metaanalysis. BMC Res Notes. 2013; 6: 184.
316. Gautam V.K., Sambandam B., Singh S., et al. The role of tranexamic acid in reducing blood loss in total knee replacement. J Clin Orthop Trauma. 2013; 4: 36–9.
317. Li Z.J., Fu X., Xing D., et al. Is tranexamic acid effective and safe in spinal surgery? A meta-analysis of randomized controlled trials. Eur Spine J. 2013; 22: 1950–7.
318. Oremus K., Sostaric S., Trkulja V., Haspl M. Infl uence of tranexamic acid on postoperative autologous blood retransfusion in primary total hip and knee arthroplasty: A randomized controlled trial. Transfusion. 2014; 54: 31–41.
319. Pachauri A., Acharya K.K., Tiwari A.K. The effect of tranexamic acid on hemoglobin levels during total knee arthroplasty. Am J Ther. 2014; 21: 366–70.
320. Shen P.F., Hou W.L., Chen J.B., et al. Effectiveness and safety of tranexamic acid for total knee arthroplasty: A prospective randomized controlled trial. Med Sci Monit. 2015; 21: 576–58
321. Tan J., Chen H., Liu Q., et al. A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty. J Surg Res. 2013; 184: 880–7.
322. Yang B., Li H., Wang D., et al. Systematic review and meta-analysis of perioperative intravenous tranexamic acid use in spinal surgery. PLoS ONE. 2013; 8: e55436.
323. Zhang F., Wang K., Li F.N., et al. Effectiveness of tranexamic acid in reducing blood loss in spinal surgery: A meta-analysis. BMC Musculoskelet Disord. 2014; 15: 448.
324. Poeran J., Rasul R., Suzuki S., et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: Retrospective analysis of effectiveness and safety. BMJ. 2014; 349: g4829.
325. Goz V., Slobodyanyuk K., Cheriyan T., et al. Antifibrinolytics reduce blood loss in adult spinal deformity surgery: A prospective randomized controlled trial. Spine J. 2013; 13(9 Suppl): S1.
326. Antonopoulou E., Digas G., Meletiadis G., et al. The effectiveness of tranexamic acid in total knee replacement. Reg Anesth Pain Med. 2013; 38: E177.
327. Tengborn L., Blomback M., Berntorp E. Tranexamic acid: An old drug still going strong and making a revival. Thromb Res. 2015; 135: 231–42.
328. Alshryda S., Mason J., Sarda P., et al. Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: A randomized controlled trial (TRANX-H). J Bone Joint Surg Am. 2013; 95: 1969–74.
329. Alshryda S., Mason J., Vaghela M., et al. Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: A randomized controlled trial (TRANX-K). J Bone Joint Surg Am. 2013; 95: 1961–8.
330. Alshryda S., Sukeik M., Sarda P., et al. A systematic review and metaanalysis of the topical administration of tranexamic acid in total hip and knee replacement. Bone Joint J. 2014; 96-B: 1005–15.
331. Chang C.H., Chang Y., Chen D.W., et al. Topical tranexamic acid reduces blood loss and transfusion rates associated with primary total hip arthroplasty. Clin Orthop Relat Res. 2014; 472: 1552–7.
332. Gilbody J., Dhotar H.S., Perruccio A.V., Davey J.R. Topical tranexamic acid reduces transfusion rates in total hip and knee arthroplasty. J Arthroplasty. 2014; 29: 681–4.
333. Gomez-Barrena E., Ortega-Andreu M., Padilla-Eguiluz N.G., et al. Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: A double-blind, randomized, controlled, noninferiority clinical trial. J Bone Joint Surg Am. 2014; 96: 1937–44.
334. Ageno W., Gallus A.S., Wittkowsky A., et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e44S–88S.
335. Kerebel D., Joly L.M., Honnart D., et al. A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal. Crit Care. 2013; 17: R4.
336. Spahn D.R., Bouillon B., Cerny V., et al. Management of bleeding and coagulopathy following major trauma: An updated European guideline. Crit Care. 2013; 17: R76.
337. Tazarourte K., Riou B., Tremey B., et al. Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study). Crit Care. 2014; 18: R81.
338. Toth P., van Veen J.J., Robinson K., et al. Real world usage of PCC to ‘rapidly’ correct warfarin induced coagulopathy. Blood Transfus. 2013; 11: 500–5.
339. Goldstein J.N., Refaai M.A., Milling T.J. Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: A phase 3b, open-label, noninferiority, randomised trial. Lancet. 2015; 385: 2077–87.
340. Quinlan D.J., Eikelboom J.W., Weitz J.I. Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. Circulation. 2013; 128: 1179–81.
341. Sarode R., Milling T.J. Jr., Refaai M.A., et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: A randomized, plasma-controlled, phase IIIb study. Circulation. 2013; 128: 1234–43.
342. Sarode R. Four-factor prothrombin complex concentrate versus plasma for urgent vitamin K antagonist reversal: New evidence. Clin Lab Med. 2014; 34: 613–21.
343. Hickey M., Gatien M., Taljaard M., et al. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation. 2013; 128: 360–4.
344. Milling T.J. Jr., Refaai M.A., Goldstein J.N., et al. Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: Exploratory analyses of two randomized, plasma-controlled studies. Ann Emerg Med. 2016; 67: 96.e5–105.e5.
345. Llau J.V., Acosta F.J., Escolar G., et al. Multidisciplinary consensus document on the management of massive haemorrhage (HEMOMAS document). Med Intensiva. 2015; 39: 483–504.
346. Sadaka F. Prothrombin complex concentrates for warfarin-related intracranial hemorrhage: should they replace fresh-frozen plasma? J Blood Disorders Transf. 2012; 3: e104.
347. Rodgers G.M. Prothrombin complex concentrates in emergency bleeding disorders. Am J Hematol. 2012; 87: 898–902.
348. Yates S.G., Sarode R. New strategies for effective treatment of vitamin K antagonist-associated bleeding. J Thromb Haemost 2015; 13(Suppl 1): S180–6.
349. Schiele F., van Ryn J., Litzenburger T., et al. Structure-guided residence time optimization of a dabigatran reversal agent. MAbs. 2015; 7: 871–80.
350. Lu G., DeGuzman F.R., Hollenbach S.J., et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013; 19: 446–51.
351. Marlu R., Hodaj E., Paris A., et al. Effect of nonspecific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: A randomized crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012; 108: 217–24.
352. Whalley D., Skappak C., Lang E.S. The need to clot: A review of current management strategies for adverse bleeding events with new oral anticoagulants. Minerva Anestesiol. 2014; 80: 821–30.
353. Lazo-Langner A., Villa-Marquez R., Hernandez-Hernandez D., et al. Intrahospital correlation of the international normalized ratio. Clin Appl Thromb Hemost. 2009; 15: 220–4.
354. Dickneite G. Prothrombin complex concentrates as reversal agents for new oral anticoagulants: Lessons from preclinical studies with Beriplex. Clin Lab Med. 2014; 34: 623–35.
355. Herzog E., Kaspereit F., Krege W., et al. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage. J Thromb Haemost. 2015; 13: 2220–6.
356. Herzog E., Kaspereit F., Krege W., et al. Effective reversal of edoxabanassociated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage. Anesthesiology. 2015; 122: 387–98.
357. Hoffman M., Volovyk Z., Monroe D.M. Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate. Anesthesiology. 2015; 122: 353–62.
358. Pragst I., Zeitler S.H., Doerr B., et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost. 2012; 10: 1841–8.
359. Godier A., Gouin-Thibault I., Rosencher N., et al. Management of direct oral anticoagulants for invasive procedures. J Mal Vasc. 2015; 40: 173–81.
360. Grottke O., van Ryn J., Spronk H.M., Rossaint R. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care. 2014; 18: R27.
361. Zhou W., Zorn M., Nawroth P., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke. 2013; 44: 771–8.
362. Zhou W., Schwarting S., Illanes S., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011; 42: 3594–9.
363. Miesbach W., Seifried E. New direct oral anticoagulants: Current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost. 2012; 108: 625–32.
364. Dickneite G., Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): What is the evidence? Thromb Haemost. 2014; 111: 189–98.
365. Liotta E.M., Levasseur-Franklin K.E., Naidech A.M. Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban. Curr Opin Crit Care. 2015; 21: 127–33.
366. Levy J.H., Faraoni D., Spring J.L., et al. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology. 2013; 118: 1466–74.
367. Haas T., Fries D., Velik-Salchner C., et al. Fibrinogen in craniosynostosis surgery. Anesth Analg. 2008; 106: 725–31.
368. El Kady N., Khedr H., Yosry M., El Mekawi S. Perioperative assessment of coagulation in paediatric neurosurgical patients using thromboelastography. Eur J Anaesthesiol. 2009; 26: 293–7.
369. Miller B.E., Guzzetta N.A., Tosone S.R., et al. Tissue factor-activated thromboelastograms in children undergoing cardiac surgery: Baseline values and comparisons. Anesth Analg. 2003; 97: 1289–93.
370. Haizinger B., Gombotz H., Rehak P., et al. Activated thrombelastogram in neonates and infants with complex congenital heart disease in comparison with healthy children. Br J Anaesth. 2006; 97: 545–52.
371. Romlin B.S., Wahlander H., Berggren H., et al. Intraoperative thromboelastometry is associated with reduced transfusion prevalence in pediatric cardiac surgery. Anesth Analg. 2011; 112: 30–6.
372. Haas T., Spielmann N., Restin T., et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: A prospective randomised controlled trial. Br J Anaesth. 2015; 115: 234–43.
373. Haas T., Mauch J., Weiss M., Schmugge M. Management of dilutional coagulopathy during pediatric major surgery. Transfus Med Hemother. 2012; 39: 114–9.
374. Niebler R.A., Gill J.C., Brabant C.P., et al. Thromboelastography in the assessment of bleeding following surgery for congenital heart disease. World J Pediatr Congenit Heart Surg. 2012; 3: 433–8.
375. Romlin B.S., Wahlander H., Synnergren M., et al. Earlier detection of coagulopathy with thromboelastometry during pediatric cardiac surgery: A prospective observational study. Paediatr Anaesth. 2013; 23: 222–7.
376. Ziegler B., Schimke C., Marchet P., et al. Severe pediatric blunt trauma: Successful ROTEM-guided hemostatic therapy with fibrinogen concentrate and no administration of fresh frozen plasma or platelets. Clin Appl Thromb Hemost. 2013; 19: 453–9.
377. Faraoni D., Willems A., Romlin B.S., et al. Development of a specific algorithm to guide haemostatic therapy in children undergoing cardiac surgery: A singlecentre retrospective study. Eur J Anaesthesiol. 2015; 32: 320–9.
378. Haas T., Goobie S., Spielmann N., et al. Improvements in patient blood management for pediatric craniosynostosis surgery using a ROTEM((R))-assisted strategy: Feasibility and costs. Paediatr Anaesth. 2014; 24: 774–80.
379. Hazle M.A., Gajarski R.J., Yu S., et al. Fluid overload in infants following congenital heart surgery. Pediatr Crit Care Med. 2013; 14: 44–9.
380. Hassinger A.B., Wald E.L., Goodman D.M. Early postoperative fluid overload precedes acute kidney injury and is associated with higher morbidity in pediatric cardiac surgery patients. Pediatr Crit Care Med. 2014; 15: 131–8.
381. Seguin J., Albright B., Vertullo L., et al. Extent, risk factors, and outcome of fluid overload after pediatric heart surgery. Crit Care Med. 2014; 42: 2591–9.
382. Bolliger D., Gorlinger K., Tanaka K.A. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology. 2010; 113: 1205–19.
383. Goobie S.M., Meier P.M., Sethna N.F., et al. Population pharmacokinetics of tranexamic acid in paediatric patients undergoing craniosynostosis surgery. Clin Pharmacokinet. 2013; 52: 267–76.
384. Wesley M.C., Pereira L.M., Scharp L.A., et al. Pharmacokinetics of tranexamic acid in neonates, infants, and children undergoing cardiac surgery with cardiopulmonary bypass. Anesthesiology. 2015; 122: 746–58.
385. Faraoni D., Rozen L., Willems A., et al. Experimental model of hyperfibrinolysis designed for rotational thromboelastometry in children with congenital heart disease. Blood Coagul Fibrinolysis. 2015; 26: 290–7.
386. Huntington J.T., Royall N.A., Schmidt C.R. Minimizing blood loss during hepatectomy: A literature review. J Surg Oncol. 2014; 109: 81–8.
387. Li Z., Sun Y.M., Wu F.X., et al. Controlled low central venous pressure reduces blood loss and transfusion requirements in hepatectomy. World J Gastroenterol. 2014; 20: 303–9.
388. Lekerika N., Gutierrez Rico R.M., Arco Vazquez J., et al. Predicting fluid responsiveness in patients undergoing orthotopic liver transplantation: Effects on intraoperative blood transfusion and postoperative complications. Transplant Proc. 2014; 46: 3087–91.
389. Massicotte L., Denault A.Y., Thibeault L., et al. Relationship between conventional coagulation tests and bleeding for 600 consecutive liver transplantations. Transplantation. 2014; 98: e13–5.
390. Krzanicki D., Sugavanam A., Mallett S. Intraoperative hypercoagulability during liver transplantation as demonstrated by thromboelastography. Liver Transpl. 2013; 19: 852–61.
391. Leon-Justel A., Noval-Padillo J.A., Alvarez-Rios A.I., et al. Point-of-care haemostasis monitoring during liver transplantation reduces transfusion requirements and improves patient outcome. Clin Chim Acta. 2015; 446: 277–83.
392. Fayed N.A., Abdallah A.R., Khalil M.K., Marwan IK. Therapeutic rather than prophylactic platelet transfusion policy for severe thrombocytopenia during liver transplantation. Platelets. 2014; 25: 576–86.
393. Schofi eld N., Sugavanam A., Thompson K., Mallett S.V. No increase in blood transfusions during liver transplantation since the withdrawal of aprotinin. Liver Transpl. 2014; 20: 584–90.
394. Roberts I., Coats T., Edwards P., et al. HALT-IT — tranexamic acid for the treatment of gastrointestinal bleeding: Study protocol for a randomized controlled trial. Trials. 2014; 15: 450.
395. Corbett C., Mangat K., Olliff S., Tripathi D. The role of transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the management of variceal hemorrhage. Liver Int. 2012; 32: 1493–1504.
396. Garcia-Pagan J.C., Di Pascoli M., Caca K., et al. Use of early-TIPS for high risk variceal bleeding: Results of a post-RCT surveillance study. J Hepatol. 2013; 58: 45–50.
397. Al-Jaghbeer M., Yende S. Blood transfusion for upper gastrointestinal bleeding: Is less more again? Crit Care. 2013; 17: 325.
398. Jairath V., Kahan B.C., Gray A., et al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): A pragmatic, openlabel, cluster randomised feasibility trial. Lancet. 2015; 386: 137–44.
399. de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015; 63: 743–52.
400. Tripathi D., Stanley A.J., Hayes P.C., et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015; 64: 1680– 1704.
401. Ranghino A., Mella A., Borchiellini A., et al. Assessment of platelet function analyzer (PFA-100) in kidney transplant patients before renal allograft biopsy: A retrospective single-center analysis. Transplant Proc. 2014; 46: 2259–62.
402. Mannucci P.M. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood. 1997; 90: 2515–21.
403. Manno C., Bonifati C., Torres D.D., et al. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: A randomized controlled trial. Am J Kidney Dis. 2011; 57: 850–5.
404. Anandagoda N., Jayawardene S., Macdougall I.C., Shah S. Desmopressin use prior to renal transplant biopsy — does it fi t? Clin Kidney J. 2014; 7: 602–4.
405. Devereaux P.J., Mrkobrada M., Sessler D.I., et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014; 370: 1494–1503.
406. Au A.G., Majumdar S.R., McAlister F.A. Preoperative thienopyridine use and outcome safter surgery: A systematic review. Am J Med. 2012; 125: 87–99.e1.
407. Smith P.K., Goodnough L.T., Levy J.H., et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: Risk-adjusted retrospective data analysis. J Am Coll Cardiol. 2012; 60: 388–96.
408. Price M.J., Walder J.S., Baker B.A., et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirintreated patients with stable coronary disease: The recovery trial. J Am Coll Cardiol. 2012; 59: 2338–43.
409. Godier A., Taylor G., Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med. 2015; 372: 196–7.
410. Baber U., Mehran R., Sharma S.K., et al. Impact of the everolimus-eluting stent on stent thrombosis: A meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011; 58: 1569–77.
411. Feres F., Costa R.A., Abizaid A., et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial. JAMA. 2013; 310: 2510–22.
412. Hawn M.T., Graham L.A., Richman J.S., et al. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA. 2013; 310: 1462–72.
413. Fazavana J., Bianchini E.P., Saller F., et al. A chemically-modifi ed inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity. J Thromb Haemost. 2013; 11: 1128–36.
414. Elmer J., Wittels K.A. Emergency reversal of pentasaccharide anticoagulants: A systematic review of the literature. Transfus Med. 2012; 22: 108–15.
415. Clark N.P., Witt D.M., Davies L.E., et al. Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med. 2015; 175: 1163–8.
416. Douketis J.D., Spyropoulos A.C., Kaatz S., et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015; 373: 823–33.
417. Kim T.H., Kim J.Y., Mun H.S., et al. Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in nonvalvular atrial fibrillation patients: A multicenter propensity-matched analysis. J Thromb Haemost. 2015; 13: 182–90.
418. Douketis J.D., Spyropoulos A.C., Spencer F.A., et al. Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e326S–e350S.
419. Colomina M.J., Diez Lobo A., Garutti I., et al. Perioperative use of prothrombin complex concentrates. Minerva Anestesiol. 2012; 78: 358–68.
420. Makris M., Van Veen J.J., Tait C.R., et al., British Committee for Standards in Hematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2013; 160: 35–46.
421. Pernod G., Godier A., Gozalo C., et al., French National Authority for Health. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res. 2010; 126: e167–74.
422. Tran H.A., Chunilal S.D., Harper P.L., et al. An update of consensus guidelines for warfarin reversal. Med J Aust. 2013; 198: 198–9.
423. Buller H.R., Prins M.H., Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287–97.
424. Cohen A.T., Spiro T.E., Buller H.R., et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013; 368: 513–23.
425. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9–19.
426. Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799–808.
427. Goldhaber S.Z., Leizorovicz A., Kakkar A.K., et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011; 365: 2167–77.
428. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011; 365: 699–708.
429. Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093–104.
430. Hokusai-VTE Investigators, Buller H.R., Decousus H., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406–15.
431. Wang X., Mondal S., Wang J., et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014; 14: 147–54.
432. Lehmann T., Hofer K.E., Baumann M., et al. Massive human rivaroxaban overdose. Thromb Haemost. 2014; 112: 834–6.
433. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124: 1573–9.
434. Glund S., Stangier J., Schmohl M., et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: A randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015; 386: 680–90.
435. Pollack C.V. Jr., Reilly P.A., Eikelboom J., et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015; 373: 511–20.
436. Siegal D.M., Curnutte J.T., Connolly S.J., et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015; 373: 2413–24.
437. Sie P., Samama C.M., Godier A., et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis. 2011; 104: 669–76.
438. Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist anticoagulants in patients with nonvalvular atrial fi brillation. Europace. 2015; 17: 1467–1507.
439. Thompson C.A., Kyle R., Gertz M., et al. Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol. 2010; 85: 171–3.
440. Franchini M., Lippi G., Manzato F., et al. Hemostatic abnormalities in endocrine and metabolic disorders. Eur J Endocrinol. 2009; 162: 439–51.
441. Vescovi P.P., Favaloro E., Lippi G, et al. The spectrum of coagulation abnormalities in thyroid disorders. Semin Thromb Hemost. 2011; 37: 7–10.
442. Michiels J.J., Schroyens W., Bememan Z., van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: Reversal after treatment with thyroxine. Clin Appl Thromb Hemost. 2001; 7: 113–5.
443. Chadarevian R., Bruckert E., Leenhardt L., et al. Components of the fi brinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab. 2001; 86: 732–7.
444. Akinci B., Comlekci A., Ali Ozcan M., et al. Elevated Thrombin Activatable Fibrinolysis Inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement. Endocr J. 2007; 54: 45–52.
445. Chadarevian R., Jublanc C., Bruckert E., et al. Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism. J Endocrinol Investig. 2005; 28: 398–404.
446. Franchini M., Zugni C., Veneri D., et al. High prevalence of acquired von Willebrand’s syndrome in patients with thyroid diseases undergoing thyroid surgery. Haematologica. 2004; 89: 1341–6.
447. Franchini M., Castaman G., Coppola A., et al. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus. 2015; 13: 498–513.
448. Kennedy J.M., Van Rij A.M., Spears G.F., et al. Polypharmacy in a general surgical unit and consequences of drug withdrawal. Br J Clin Pharmacol. 2008; 49: 353–62.
449. McCloskey D.J., Postolache T.T., Vittone B.J., et al. Selective serotonin reuptake inhibitors: Measurement of effect on platelet function. Transl Res. 2008; 151: 168–72.
450. de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function. Drugs Aging. 2011; 28: 345–67.
451. Meijer W.E.E., Heerdink E.R., Nolen W.A., et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004; 164: 2367.
452. Castanheira L., Palmeiro A., Fresco P., Macedo A.F. Chronic medication in the perioperative period: Usage profile and risk management. Acta Med Port. 2011; 24: 893–8.
453. Sayadipour A., Mago R., Kepler C.K., et al. Antidepressants and the risk of abnormal bleeding during spinal surgery: A case — control study. Eur Spine J. 2012; 21: 2070–8.
454. van Haelst I.M.M., Egberts T.C.G., Doodeman H.J., et al. Use of serotonergic antidepressants and bleeding risk in orthopedic patients. Anesthesiology. 2010; 112: 631–6.
455. Seitz D.P., Bell C.M., Gill S.S., et al. Risk of perioperative blood transfusions and postoperative complications associated with serotonergic antidepressants in older adults undergoing hip fracture surgery. J Clin Psychopharmacol. 2013; 33: 790–8.
456. Dall M., Primdahl A., Damborg F., et al. The association between use of serotonergic antidepressants and perioperative bleeding during total hip arthroplasty: A cohort study. Basic Clin Pharmacol Toxicol. 2014; 115: 277–81.
457. Schutte H.J., Jansen S., Schafroth M.U., et al. SSRIs increase risk of blood transfusion in patients admitted for hip surgery. PLoS ONE. 2014; 9: e95906.
458. Jeong B.-O., Kim S.-W., Kim S.-Y., et al. Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery. Psychosomatics. 2014; 55: 213–20.
459. Gahr M., Zeiss R., Lang D., et al. Risk of bleeding related to selective and nonselective serotonergic antidepressants: A case/noncase approach using data from two pharmacovigilance databases. Pharmacopsychiatry. 2015; 48: 19–24.
460. Mahdanian A.A., Rej S., Bacon S.L., et al. Serotonergic antidepressants and perioperative bleeding risk: A systematic review. Expert Opin Drug Saf. 2014; 13: 695–704.
461. Gahr M., Zeiss R., Lang D., et al. Association between haemorrhages and treatment with selective and nonselective serotonergic antidepressants: Possible implications of quantitative signal detection. Psychiatry Res. 2015; 229: 257–63.
462. Maschino F., Hurault-Delarue C., Chebbane L., et al. Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs: Analysis of the French Spontaneous Reporting Database for a controversial ADR. Eur J Clin Pharmacol. 2012; 68: 1557–60.
463. Montastruc F., Sommet A., Bondon-Guitton E., et al. The importance of drugdrug interactions as a cause of adverse drug reactions: A pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol. 2011; 68: 767–75.
464. Nadkarni A., Oldham M.A., Howard M., Berenbaum I. Drug-drug interactions between warfarin and psychotropics: Updated review of the literature. Pharmacotherapy. 2012; 32: 932–42.
465. Cheng Y.-L., Hu H.-Y., Lin X.-H., et al. Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding. Medicine. 2015; 94: e2022.
466. Anglin R., Yuan Y., Moayyedi P., et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-infl ammatory use: A systematic review and meta-analysis. Am J Gastroenterol. 2014; 109: 811–9.
467. Jiang H.-Y., Chen H.-Z., Hu X.-J., et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: A systematic review and metaanalysis. Clin Gastroenterol Hepatol. 2015; 13: 42.e3–50.e3.
468. Wang Y.-P., Chen Y.-T., Tsai C.-F., et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry. 2014; 171: 54–61.
469. Yoon H.W., Giraldo E.A., Wijdicks E.F.M. Valproic acid and warfarin: An underrecognized drug interaction. Neurocrit Care. 2011; 15: 182–5.
470. Kose G., Arhan E., Unal B., et al. Valproate-associated coagulopathies in children during short-term treatment. J Child Neurol. 2009; 24: 1493–8.
471. Gerstner T., Teich M., Bell N., et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia. 2006; 47: 1136–43.
472. Koenig S., Gerstner T., Keller A., et al. High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: A prospective study. Blood Coagul Fibrinolysis. 2008; 19: 375–82.
473. Zighetti M.L., Fontana G., Lussana F., et al. Effects of chronic administration of valproic acid to epileptic patients on coagulation tests and primary hemostasis. Epilepsia. 2015; 56: e49–52.
474. Manohar C., Avitsian R., Lozano S., et al. The effect of antiepileptic drugs on coagulation and bleeding in the perioperative period of epilepsy surgery: The Cleveland Clinic experience. J Clin Neurosci. 2011; 18: 1180–4.
475. Cordier W., Steenkamp V. Herbal remedies affecting coagulation: A review. Pharm Biol. 2011; 50: 443–52.
476. Tsai H.-H., Lin H.-W., Lu Y.-H., et al. A review of potential harmful interactions between anticoagulant/antiplatelet agents and Chinese herbal medicines. PLoS ONE. 2013; 8: e64255.
477. McEwen B. The influence of herbal medicine on platelet function and coagulation: A narrative review. Semin Thromb Hemost. 2015; 41: 300–14.
478. Bent S., Goldberg H., Padula A., Avins A.L. Spontaneous bleeding associated with Ginkgo biloba. J Gen Intern Med. 2005; 20: 657–61.
479. Kohler S., Funk P., Kieser M. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: A randomized, placebo-controlled, double-blind study in healthy volunteers. Blood Coagul Fibrinolysis. 2004; 15: 303–9.
480. Kellermann A.J., Kloft C. Is there a risk of bleeding associated with standardized ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy. 2011; 31: 490–502.
481. Wolf H.R.D. Does ginkgo biloba special extract EGb 761 Provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500mg daily? Drugs R&D. 2006; 7: 163–72.
482. Gardner C.D., Zehnder J.L., Rigby A.J., et al. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: A randomized clinical trial. Blood Coagul Fibrinolysis. 2007; 18: 787–93.
483. Kim H.-S., Kim G.-Y., Yeo C.-W., et al. The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects. Br J Clin Pharmacol. 2014; 77: 821–30.
484. Kim B.-H., Kim K.-P., Lim K.S., et al. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: An open-label, randomized, two-period, two-treatment, two-sequence, singledose crossover study in healthy Korean male volunteers. Clin Ther. 2010; 32: 380–90.
485. McEwen B. The influence of diet and nutrients on platelet function. Semin Thromb Hemost. 2014; 40: 214–226.
486. McEwen B., Morel-Kopp M.-C., Tofl er G., Ward C. The effect of omega-3 polyunsaturated fatty acids on fi brin and thrombin generation in healthy subjects and subjects with cardiovascular disease. Semin Thromb Hemost. 2015; 41: 315–22.
487. Mensah P.K., Gooding R. Surgery in patients with inherited bleeding disorders. Anaesthesia. 2015; 70(Suppl 1): 112–20; e39–40.
488. Rodeghiero F., Castaman G., Tosetto A., et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: An international, multicenter study. J Thromb Haemost. 2005; 3: 2619–26.
489. Azzam H.A., Goneim H.R., El-Saddik A.M., et al. The condensed MCMDM-1 VWD bleeding questionnaire as a predictor of bleeding disorders in women with unexplained menorrhagia. Blood Coagul Fibrinolysis. 2012; 23: 311–5.
490. Bidlingmaier C., Grote V., Budde U., et al. Prospective evaluation of a pediatric bleeding questionnaire and the ISTH bleeding assessment tool in children and parents in routine clinical practice. J Thromb Haemost. 2012; 10: 1335–41.
491. Lowe G.C., Lordkipanidze M., Watson S.P., UK GAPP study group. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. J Thromb Haemost. 2013; 11: 1663–8.
492. Bowman M., Mundell G., Grabell J., et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost. 2008; 6: 2062–6.
493. Hyatt S.A., Wang W., Kerlin B.A., O’Brien S.H. Applying diagnostic criteria for type 1 von Willebrand disease to a pediatric population. Pediatr Blood Cancer. 2009; 52: 102–7.
494. Rodeghiero F., Tosetto A., Castaman G. How to estimate bleeding risk in mild bleeding disorders. J Thromb Haemost. 2007; 5(Suppl 1): 157– 66.
495. Mauer A.C., Khazanov N.A., Levenkova N., et al. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost. 2011; 9: 100–8.
496. Quiroga T., Goycoolea M., Panes O., et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica. 2007; 92: 357–65.
497. Tosetto A. The role of bleeding history and clinical markers for the correct diagnosis of VWD. Mediterr J Hematol Infect Dis. 2013; 5: e2013051.
498. Mittal N., Naridze R., James P., et al. Utility of a Paediatric Bleeding Questionnaire as a screening tool for von Willebrand disease in apparently healthy children. Haemophilia. 2015; 21: 806–11.
499. Federici A.B., Bucciarelli P., Castaman G., et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood. 2014; 123: 4037–44.
500. Castaman G., Federici A.B., Tosetto A., et al. Different bleeding risk in type 2A and 2M von Willebrand disease: A 2-year prospective study in 107 patients. J Thromb Haemost. 2012; 10: 632–8.
501. Ahmad J., Benson G.M., McNulty O.M., et al. Surgeon and haematologist: A review of comprehensive care for patients with inherited bleeding disorders in Northern Ireland. Int J Surg. 2013; 11: 22–6.
502. Chevalier Y., Dargaud Y., Lienhart A., et al. Seventy-two total knee arthroplasties performed in patients with haemophilia using continuous infusion. Vox Sang. 2013; 104: 135–43.
503. Kulkarni R. Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: Practical aspects. Haemophilia. 2013; 19: 2–10.
504. Lingohr P., Bensoukehal S., Matthaei H., et al. Value and risk of laparoscopic surgery in hemophiliacs — experiences from a tertiary referral center for hemorrhagic diatheses. Langenbecks Arch Surg. 2014; 399: 609–18.
505. Poenaru D.V., Patrascu J.M., Andor B.C., Popa I. Orthopaedic and surgical features in the management of patients with haemophilia. Eur J Orthop Surg Traumatol. 2014; 24: 685–92.
506. Hart C., Heindl B., Spannagl M., Lison S. A standardized treatment regimen for patients with severe haemophilia A undergoing orthopaedic or trauma surgery: A single centre experience. Blood Coagul Fibrinolysis. 2015; 26: 396–402.
507. Serban M., Poenaru D., Patrascu J., et al. Risks and challenges of orthopaedic invasive interventions in haemophilia in a low-resource country. A single center experience. Hamostaseologie. 2014; 34(Suppl 1): S30–5.
508. Hermans C., Altisent C., Batorova A., et al. Replacement therapy for invasive procedures in patients with haemophilia: Literature review, European survey and recommendations. Haemophilia. 2009; 15: 639–58.
509. Sikkema T., Boerboom A.L., Meijer K. A comparison between the complications and long-term outcome of hip and knee replacement therapy in patients with and without haemophilia: A controlled retrospective cohort study. Haemophilia. 2011; 17: 300–3.
510. Jenkins P.J., Ekrol I., Lawson G.M. Total knee replacement in patients with haemophilia: The Scottish experience. Scott Med J. 2013; 58: 223–7.
511. Rogenhofer S., Hauser S., Breuer A., et al. Urological surgery in patients with hemorrhagic bleeding disorders Hemophilia A, Hemophilia B, von Willebrand disease: A retrospective study with matched pairs analysis. World J Urol. 2013; 31: 703–7.
512. Karaman M.I., Zulfi kar B., Ozturk M.I., et al. Circumcision in bleeding disorders: Improvement of our cost effective method with diathermic knife. Urol J. 2014; 11: 1406–10.
513. Barg A., Barg K., Wiewiorski M., et al. Total ankle replacement in patients with bleeding disorders. Orthopade. 2015; 44: 623–38.
514. Westberg M., Paus A.C., Holme P.A., Tjonnfjord G.E. Haemophilic arthropathy: Long-term outcomes in 107 primary total knee arthroplasties. Knee. 2014; 21: 147–50.
515. Cancienne J.M., Werner B.C., Browne J.A. Complications after TKA in patients with hemophilia or Von Willebrand’s disease. J Arthroplasty. 2015; 30: 2285–9.
516. Aryal K.R., Wiseman D., Siriwardena A.K., et al. General surgery in patients with a bleeding diathesis: How we do it. World J Surg. 2011; 35: 2603–10.
517. Goldmann G., Holoborodska Y., Oldenburg J., et al. Perioperative management and outcome of general and abdominal surgery in hemophiliacs. Am J Surg. 2010; 199: 702–7.
518. Panotopoulos J., Ay C., Trieb K., et al. Surgical treatment of the haemophilic pseudotumour: A single centre experience. Int Orthop. 2012; 36: 2157–62.
519. Lim M.Y., Nielsen B., Ma A., Key N.S. Clinical features and management of haemophilic pseudotumours: A single US centre experience over a 30- year period. Haemophilia. 2014; 20: e58–62.
520. Inokawa Y., Sugimoto H., Kanda M., et al. Hepatectomy for hepatocellular carcinoma in patients with hemophilia. J Hepatobiliary Pancreat Sci. 2014; 21: 824–8.
521. Lim M.Y., Pruthi R.K. Outcomes of management of acute coronary syndrome in patients with congenital bleeding disorders: A single center experience and review of the literature. Thromb Res. 2012; 130: 316–22.
522. Tuinenburg A., Damen S.A., Ypma P.F., et al. Cardiac catheterization and intervention in haemophilia patients: Prospective evaluation of the 2009 institutional guideline. Haemophilia. 2013; 19: 370–7.
523. Fogarty P.F., Mancuso M.E., Kasthuri R, et al. Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia. 2015; 21: 589–97.
524. Tintillier V., Branche J., Maunoury V., et al. Colonoscopy in patients with haemophilia: The duration of clotting factor coverage must be adjusted to suit the procedure. Haemophilia. 2013; 19: e296–8.
525. Escobar M., Maahs J., Hellman E., et al. Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: Perspectives and best practices derived from experienced treatment centres. Haemophilia. 2012; 18: 971–81.
526. Shapiro A., Cooper D.L. U.S. survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors. Haemophilia. 2012; 18: 400–5.
527. Caviglia H., Candela M., Landro M.E., et al. Haemophilia pseudotumours in patients with inhibitors. Haemophilia. 2015; 21: 681–5.
528. Stoof S.C.M., van Steenbergen H.W., Zwagemaker A., et al. Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: A retrospective survey. Haemophilia. 2015; 21: 505–12.
529. Ljung R.C., Knobe K. How to manage invasive procedures in children with haemophilia. Br J Haematol. 2012; 157: 519–28.
530. Sun G.H., Auger K.A., Aliu O., et al. Posttonsillectomy hemorrhage in children with von Willebrand disease or hemophilia. JAMA Otolaryngol Head Neck Surg. 2013; 139: 245–9.
531. Watts R.G., Cook R.P. Operative management and outcomes in children with congenital bleeding disorders: A retrospective review at a single haemophilia treatment centre. Haemophilia. 2012; 18: 421–5.
532. Garcia-Matte R., Maria Constanza Beltran M., Ximena Fonseca A., Pamela Zuniga C. Management of children with inherited mild bleeding disorders undergoing adenotonsillar procedures. Int J Pediatr Otorhinolaryngol. 2012; 76: 291–4.
533. Santoro C., Hsu F., Dimichele D.M. Haemostasis prophylaxis using single dose desmopressin acetate and extended use epsilon aminocaproic acid for adenotonsillectomy in patients with type 1 von Willebrand disease. Haemophilia. 2012; 18: 200–4.
534. Jimenez-Yuste V., Prim M.P., De Diego J.I., et al. Otolaryngologic surgery in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg. 2002; 128: 1365–8.
535. Sanchez-Luceros A., Meschengieser S.S., Woods A.I., et al. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history. Thromb Haemost. 2010; 104: 984–9.
536. Dunn A.L., Cox Gill J. Adenotonsillectomy in patients with desmopressin responsive mild bleeding disorders: A review of the literature. Haemophilia. 2010; 16: 711–6.
537. Rodriguez K.D., Sun G.H., Pike F., et al. Posttonsillectomy bleeding in children with von Willebrand disease: A single-institution experience. Otolaryngol Head Neck Surg. 2010; 142: 715–21.
538. Witmer C.M., Elden L., Butler R.B., et al. Incidence of bleeding complications in pediatric patients with type 1 von Willebrand disease undergoing adenotonsillar procedures. J Pediatr. 2009; 155: 68–72.
539. Kearney S., Sharathkumar A., Rodriguez V., et al. Neonatal circumcision in severe haemophilia: A survey of paediatric haematologists at United States Hemophilia Treatment Centers. Haemophilia. 2015; 21: 52–7.
540. Elalfy M.S., Elbarbary N.S., Eldebeiky M.S., El Danasoury A.S. Risk of bleeding and inhibitor development after circumcision of previously untreated or minimally treated severe hemophilia A children. Pediatr Hematol Oncol. 2012; 29: 485–93.
541. Rodriguez V., Titapiwatanakun R., Moir C., et al. To circumcise or not to circumcise? Circumcision in patients with bleeding disorders. Haemophilia. 2010; 16: 272–6.
542. Yilmaz D., Akin M., Ay Y., et al. A single centre experience in circumcision of haemophilia patients: Izmir protocol. Haemophilia. 2010; 16: 888–91.
543. Sasmaz I., Antmen B., Leblebisatan G., et al. Circumcision and complications in patients with haemophilia in southern part of Turkey: Cukurova experience. Haemophilia. 2012; 18: 426–30.
544. Mansouritorghabeh H., Banihashem A., Modaresi A., Manavifar L. Circumcision in males with bleeding disorders. Mediterr J Hematol Infect Dis. 2013; 5: e2013004.
545. Peisker A., Raschke G.F., Schultze-Mosgau S. Management of dental extraction in patients with haemophilia A and B: A report of 58 extractions. Med Oral Patol Oral Cir Bucal. 2014; 19: e55–60.
546. Zanon E., Martinelli F., Bacci C., et al. Proposal of a standard approach to dental extraction in haemophilia patients. A case-control study with good results. Haemophilia. 2000; 6: 533–6.
547. Frachon X., Pommereuil M., Berthier A.M., et al. Management options for dental extraction in hemophiliacs: A study of 55 extractions (2000–2002). Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 99: 270–5.
548. Franchini M., Rossetti G., Tagliaferri A., et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia. 2005; 11: 504–9.
549. Anderson J.A., Brewer A., Creagh D., et al. Guidance on the dental management of patients with haemophilia and congenital bleeding disorders. Br Dent J. 2013; 215: 497–504.
550. Hewson I., Makhmalbaf P., Street A., et al. Dental surgery with minimal factor support in the inherited bleeding disorder population at the Alfred Hospital. Haemophilia. 2011; 17: e185–8.
551. Givol N., Hirschhorn A., Lubetsky A., et al. Oral surgery-associated postoperative bleeding in haemophilia patients: A tertiary centre’s two decade experience. Haemophilia. 2015; 21: 234–40.
552. Hirose J., Takedani H., Koibuchi T. The risk of elective orthopaedic surgery for haemophilia patients: Japanese single-centre experience. Haemophilia. 2013; 19: 951–5.
553. Wallny T.A., Strauss A.C., Goldmann G., et al. Elective total knee arthroplasty in haemophilic patients. Proposal for a clinical pathway. Hamostaseologie. 2014; 34(Suppl 1): S23–9.
554. Solimeno L.P., Mancuso M.E., Pasta G., et al. Factors influencing the longterm outcome of primary total knee replacement in haemophiliacs: A review of 116 procedures at a single institution. Br J Haematol. 2009; 145: 227–34.
555. Bolton-Maggs P.H., Chalmers E.A., Collins P.W., et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol. 2006; 135: 603–33.
556. Keeling D., Tait C., Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors’ Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia. 2008; 14: 671–84.
557. Nichols W.L., Hultin M.B., James A.H., et al. von Willebrand disease (VWD): Evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008; 14: 171–232.
558. Habermann B., Eberhardt C., Hovy L., et al. Total hip replacement in patients with severe bleeding disorders. A 30 years single center experience. Int Orthop. 2007; 31: 17–21.
559. Srivastava A., Brewer A.K., Mauser-Bunschoten E.P., et al. Guidelines for the management of hemophilia. Haemophilia. 2013; 19: e1–47.
560. Giangrande P., Calizzani G., Menichini I., et al. The European standards of Haemophilia Centres. Blood Transfus. 2014; 12(Suppl 3): s525–30.
561. Candura F., Menichini I., Calizzani G., et al. The methodology for defining the European standards for the certifi cation of Haemophilia Centres in Europe. Blood Transfus. 2014; 12(Suppl 3): s519–24.
562. Coppola A., Windyga J., Tufano A., et al. Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. Cochrane Database Syst Rev. 2015; (2): CD009961.
563. Laffan M.A., Lester W., O’Donnell J.S., et al. The diagnosis and management of von Willebrand disease: A United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014; 167: 453–65.
564. Rocino A., Coppola A., Franchini M., et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus. 2014; 12: 575–98.
565. Federici A.B., Bucciarelli P., Castaman G., et al. Management of inherited von Willebrand disease in Italy: Results from the retrospective study on 1234 patients. Semin Thromb Hemost. 2011; 37: 511–21.
566. Nitu-Whalley I.C., Griffioen A., Harrington C., Lee C.A. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol. 2001; 66: 280–4.
567. Morimoto Y., Yoshioka A., Sugimoto M., et al. Haemostatic management of intraoral bleeding in patients with von Willebrand disease. Oral Dis. 2005; 11: 243–8.
568. Revel-Vilk S., Schmugge M., Carcao M.D., et al. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease. J Pediatr Hematol Oncol. 2003; 25: 874–9.
569. Garcia-Matte R.J., Beltran M.C., Fonseca X., et al. Use of desmopressin in children with inherited platelet dysfunctions undergoing adenotonsillar procedures. Acta Otorrinolaringol Esp. 2012; 63: 115–9.
570. Leissinger C., Carcao M., Gill J.C., et al. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. Haemophilia. 2014; 20: 158–67.
571. Trigg D.E., Stergiotou I., Peitsidis P., Kadir R.A. A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia. 2012; 18: 25–33.
572. Windyga J., Dolan G., Altisent C., et al. Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: A European survey. Haemophilia. 2016; 22: 110–20.
573. Sharma R., Stein D. Hyponatremia after desmopressin (DDAVP) use in pediatric patients with bleeding disorders undergoing surgeries. J Pediatr Hematol Oncol. 2014; 36: e371–5.
574. Gill J.C., Castaman G., Windyga J., et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015; 126: 2038–46.
575. Neff A.T., Sidonio R.F. Jr. Management of VWD. Hematology Am Soc Hematol Educ Program. 2014; 2014: 536–41.
576. Castaman G. Treatment of von Willebrand disease with FVIII/VWF concentrates. Blood Transfus. 2011; 9(Suppl 2): s9–13.
577. Lillicrap D., Poon M.C., Walker I., et al. Efficacy and safety of the factor VIII/ von Willebrand factor concentrate, Haemate-P/Humate-P: Ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002; 87: 224–30.
578. Howman R., Barnes C., Curtin J., et al. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE(R), in children with von Willebrand disorder: A multicentre retrospective review. Haemophilia. 2011; 17: 463–9.
579. Gill J.C., Shapiro A., Valentino L.A., et al. Von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease. Haemophilia. 2011; 17: 895–905.
580. Mannucci P.M., Kyrle P.A., Schulman S., et al. Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand’s disease undergoing elective surgery: A pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfus. 2013; 11: 533–40.
581. Khair K., Batty P., Riat R., et al. Wilate use in 47 children with von Willebrand disease: The North London paediatric haemophilia network experience. Haemophilia. 2015; 21: e44–50.
582. Franchini M., Rossetti G., Tagliaferri A., et al. Effi cacy and safety of factor VIII/von Willebrand’s factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica. 2003; 88: 1279–83.
583. Thompson A.R., Gill J.C., Ewenstein B.M., et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/ VWF concentrate (Humate-P). Haemophilia. 2004; 10: 42–51.
584. Federici A.B., Castaman G., Franchini M., et al. Clinical use of Haemate P in inherited von Willebrand’s disease: A cohort study on 100 Italian patients. Haematologica. 2007; 92: 944–51.
585. Lethagen S., Kyrle P.A., Castaman G., et al. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: A prospective multicenter trial in elective surgery. J Thromb Haemost. 2007; 5: 1420–30.
586. Hernandez-Navarro F., Quintana M., Jimenez-Yuste V., et al. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purifi ed, doubly inactivated FVIII/VWF concentrate. Haemophilia. 2008; 14: 963–7.
587. Rivard G.E., Aledort L. Effi cacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia. 2008; 14: 271–5.
588. Viswabandya A., Mathews V., George B., et al. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI. Haemophilia. 2008; 14: 763–7.
589. Dunkley S., Baker R.I., Pidcock M., et al. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand’s disease: A prospective multicentre study. Haemophilia. 2010; 16: 615–24.
590. Federici A.B., Barillari G., Zanon E., et al. Effi cacy and safety of highly purifi ed, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: Results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia. 2010; 16: 101–10.
591. Windyga J., Lissitchkov T., Stasyshyn O., et al. Effi cacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: A prospective, open-label, uncontrolled, multicentre, phase III study. Haemophilia. 2014; 20: 651–8.
592. Castaman G., Coppola A., Zanon E., et al. Effi cacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: Results from an Italian prospective observational study in patients with von Willebrand disease. Haemophilia. 2013; 19: 82–8.
593. Batty P., Chen Y.H., Bowles L., et al. Safety and effi cacy of a von Willebrand factor/factor VIII concentrate (Wilate(R)): A single centre experience. Haemophilia. 2014; 20: 846–53.
594. Siboni S.M., Biguzzi E., Solimeno L.P., et al. Orthopaedic surgery in patients with von Willebrand disease. Haemophilia. 2014; 20: 133–40.
595. Michiels J.J., van Vliet H.H., Berneman Z., et al. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings. Acta Haematol. 2009; 121: 167–76.
596. Di Paola J., Lethagen S., Gill J., et al. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand’s disease (VWD) has limited value in dosing for surgery. Haemophilia. 2011; 17: 752–8.
597. van Vliet H.H., Kappers-Klunne M.C., Leebeek F.W., Michiels J.J. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Thromb Haemost. 2008; 100: 462–8.
598. Makris M., Colvin B., Gupta V., et al. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb Haemost. 2002; 88: 387–8.
599. Girolami A., Tasinato V., Sambado L., et al. Venous thrombosis in von Willebrand disease as observed in one centre and as reported in the literature. Blood Coagul Fibrinolysis. 2015; 26: 54–8.
600. Gill J.C., Mannucci P.M. Thromboembolic incidence with transiently elevated levels of coagulation factors in patients with von Willebrand disease treated with VWF:FVIII concentrate during surgery. Haemophilia. 2014; 20: e404–6.
601. Mannucci P.M., Franchini M., Castaman G., Federici A.B. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus. 2009; 7: 117–26.
602. Gresele P., Harrison P., Bury L., et al. Diagnosis of suspected inherited platelet function disorders: Results of a worldwide survey. J Thromb Haemost. 2014; 12: 1562–9.
603. Coppola A., Di Minno G. Desmopressin in inherited disorders of platelet function. Haemophilia. 2008; 14(Suppl 1): 31–9.
604. Alamelu J., Liesner R. Modern management of severe platelet function disorders. Br J Haematol. 2010; 149: 813–23.
605. Karger R., Donner-Banzhoff N., Muller H.H., et al. Diagnostic performance of the platelet function analyzer (PFA-100) for the detection of disorders of primary haemostasis in patients with a bleeding history — a systematic review and meta-analysis. Platelets. 2007; 18: 249–60.
606. Podda G.M., Bucciarelli P., Lussana F., et al. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: Comparison with the bleeding time. J Thromb Haemost. 2007; 5: 2393–8.
607. Marcus P.D., Nire K.G., Grooms L., et al. The power of a standardized bleeding score in diagnosing paediatric type 1 von Willebrand’s disease and platelet function defects. Haemophilia. 2011; 17: 223–37.
608. Gresele P; Subcommittee on Platelet Physiology of the International Society on Thrombosis and Hemostasis. Diagnosis of inherited platelet function disorders: Guidance from the SSC of the ISTH. J Thromb Haemost. 2015; 13: 314–22.
609. Tosetto A., Balduini C.L., Cattaneo M., et al. Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2009; 124: e13–18.
610. Rao A.K., Ghosh S., Sun L., et al. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A doubleblind placebo-controlled trial. Thromb Haemost. 1995; 74: 1071–8.
611. Koscielny J., von Tempelhoff G.F., Ziemer S., et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost. 2004; 10: 155–66.
612. Siegmund B., Pollmann H. Desmopressin parenteral in patients with VWD1, VWD 2A and thrombocytopathy. Hamostaseologie. 2011; 31(Suppl 1): S29–33.
613. Tauer J.T., Gneuss A., Lohse J.E., et al. Evaluation of desmopressin effect on primary haemostasis in pediatric patients with aspirin-like defect as hereditary thrombocytopathy. Klin Padiatr. 2011; 223: 169–72.
614. Colucci G., Stutz M., Rochat S., et al. The effect of desmopressin on platelet function: A selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. Blood. 2014; 123: 1905–16.
615. Rajpurkar M., Chitlur M., Recht M., Cooper D.L. Use of recombinant activated factor VII in patients with Glanzmann’s thrombasthenia: A review of the literature. Haemophilia. 2014; 20: 464–71.
616. Poon M.C., d’Oiron R., Zotz R.B., et al. The international, prospective Glanzmann Thrombasthenia Registry: Treatment and outcomes in surgical intervention. Haematologica. 2015; 100: 1038–44.
617. Di Minno G., Zotz R.B., d’Oiron R., et al. The international, prospective Glanzmann Thrombasthenia Registry: Treatment modalities and outcomes of nonsurgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica. 2015; 100: 1031–7.
618. Balduini C.L., Savoia A., Seri M. Inherited thrombocytopenias frequently diagnosed in adults. J Thromb Haemost. 2013; 11: 1006–19.
619. Weber C.F., Gorlinger K., Byhahn C., et al. Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy. Eur J Anaesthesiol. 2011; 28: 57–62.
620. Hennewig U., Laws H.J., Eisert S., Gobel U. Bleeding and surgery in children with Glanzmann thrombasthenia with and without the use of recombinant factor VIIa. Klin Padiatr. 2005; 217: 365–70.
621. Blanchette V.S., Key N.S, Ljung L.R., et al. Definitions in hemophilia: Communication from the SSC of the ISTH. J Thromb Haemost. 2014; 12: 1935–9.
622. Franchini M., Favaloro E.J., Lippi G. Mild hemophilia A. J Thromb Haemost. 2010; 8: 421–32.
623. Franchini M., Castaman G., Coppola A., et al. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus. 2015; 13: 498–513.
624. Young G., Sorensen B., Dargaud Y., et al. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: Current state of art and future perspectives. Blood. 2013; 121: 1944–50.
625. Srivastava A., Chandy M., Sunderaj G.D., et al. Low-dose intermittent factor replacement for postoperative haemostasis in haemophilia. Haemophilia. 1998; 4: 799–801.
626. Wong J.M., Mann H.A., Goddard N.J. Perioperative clotting factor replacement and infection in total knee arthroplasty. Haemophilia. 2012; 18: 607–12.
627. Franchini M. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: Recombinant is better. Blood Transfus. 2010; 8: 292–6.
628. Mannucci P.M. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: Plasma-derived is better. Blood Transfus. 2010; 8: 288–91.
629. Fischer K., Lassila R., Peyvandi F, et al. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost. 2015; 113: 968–75.
630. Windyga J., Rusen L., Gruppo R, et al. BDDrFVIII (Moroctocog alfa [AFCC]) for surgical haemostasis in patients with haemophilia A: Results of a pivotal study. Haemophilia. 2010; 16: 731–9.
631. Santagostino E., Lentz S.R., Misgav M., et al. Safety and effi cacy of turoctocog alfa (NovoEight(R)) during surgery in patients with haemophilia A: Results from the multinational guardian clinical trials. Haemophilia. 2015; 21: 34–40.
632. Mancuso M.E., Mannucci P.M., Rocino A., et al. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost. 2012; 10: 781–90.
633. Marcucci M., Mancuso M.E., Santagostino E., et al. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patientlevel meta-analysis. Thromb Haemost. 2015; 113: 958–67.
634. Ragni M.V., Pasi K.J., White G.C., et al. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia. 2002; 8: 91–7.
635. Lissitchkov T., Matysiak M., Zavilska K., et al. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine((R)), a high-purity factor IX concentrate, in patients with severe haemophilia B. Haemophilia. 2011; 17: 590–6.
636. Mauser-Bunschoten E.P., Kleine Budde I., Lopaciuk S., et al. An ultrapure plasma-derived monoclonal antibody-purifi ed factor IX concentrate (Nonafact(R)), results of phase III and IV clinical studies. Haemophilia. 2011; 17: 439–45.
637. Quon D.V., Logan L. Safety and effi cacy of plasma-derived coagulation factor IX concentrate (AlphaNine(R) SD) in patients with haemophilia B undergoing surgical intervention: A single institution retrospective analysis. Haemophilia. 2011; 17: e196–201.
638. Perez-Garrido R., Alonso N., Jimenez-Yuste V., et al. Efficacy of factor IX Grifols((R)) in surgery: Experience of an international multicenter retrospective study. Haemophilia. 2012; 18: e372–3.
639. Uprichard J., Adamidou D., Goddard N.J., et al. Factor IX replacement to cover total knee replacement surgery in haemophilia B: A single-centre experience, 2000-2010. Haemophilia. 2012; 18: 46–9.
640. Powell J.S., Apte S., Chambost H., et al. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol. 2015; 168: 124–34.
641. Batorova A., Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol. 2000; 110: 715–20.
642. Schulman S., Loogna J., Wallensten R. Minimizing factor requirements for surgery without increased risk. Haemophilia. 2004; 10(Suppl 4): 35–40.
643. Stieltjes N., Altisent C., Auerswald G., et al. Continuous infusion of Bdomain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: Clinical experience. Haemophilia. 2004; 10: 452–8.
644. Negrier C., Shapiro A., Berntorp E., et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients. Thromb Haemost. 2008; 100: 217–23.
645. Auerswald G., Bade A., Johne J., et al. Prospective study of continuous infusion with Beriate(R) P in patients with severe haemophilia A undergoing surgery: A subgroup analysis. Thromb Res. 2014; 134(Suppl 1): S43–7.
646. Eckhardt C.L., Menke L.A., van Ommen C.H., et al. Intensive peri-operative use of factor VIII and the Arg593–>Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost. 2009; 7: 930–7.
647. Auerswald G., Bade A., Haubold K., et al. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: A prospective study. Haemophilia. 2013; 19: 438–44.
648. Meijer K., Rauchensteiner S., Santagostino E., et al. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: Noninterventional, observational study in patients with severe haemophilia A. Haemophilia. 2015; 21: e19–25.
649. Boban A., Lambert C., Hermans C. The use of short-term central venous catheters for optimizing continuous infusion of coagulation factor concentrate in haemophilia patients undergoing major surgical procedures. Haemophilia. 2015; 21: e364–8.
650. Iorio A., Matino D., D’Amico R., Makris M. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev. 2010; (8): CD004449.
651. Johansson P.I., Ostrowski S.R. Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders. Drug Des Devel Ther. 2010; 4: 107–16.
652. Valentino L.A. Assessing the benefi ts of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia. 2010; 16: 263–71.
653. Birschmann I., Klamroth R., Eichler H., et al. Results of the WIRK prospective, noninterventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders. Haemophilia. 2013; 19: 679–85.
654. Rangarajan S., Yee T.T., Wilde J. Experience of four UK comprehensive care centres using FEIBA(R) for surgeries in patients with inhibitors. Haemophilia. 2011; 17: 28–34.
655. Zulfi kar B., Aydogan G., Salcioglu Z., et al. Effi cacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: A multicentre registry in Turkey. Haemophilia. 2012; 18: 383–91.
656. Rangarajan S., Austin S., Goddard N.J., et al. Consensus recommendations for the use of FEIBA((R)) in haemophilia A patients with inhibitors undergoing elective orthopaedic and nonorthopaedic surgery. Haemophilia. 2013; 19: 294–303.
657. Holmstrom M., Tran H.T., Holme P.A. Combined treatment with APCC (FEIBA(R)) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A — a two-centre experience. Haemophilia. 2012; 18: 544–9.
658. Valentino L.A., Cooper D.L., Goldstein B. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia. 2011; 17: 579–89.
659. Takedani H., Shima M., Horikoshi Y., et al. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan. Haemophilia. 2015; 21: 374–9.
660. Boadas A., Fernandez-Palazzi F., De Bosch N.B., et al. Elective surgery in patients with congenital coagulopathies and inhibitors: Experience of the National Haemophilia Centre of Venezuela. Haemophilia. 2011; 17: 422–7.
661. Young G., Cooper D.L., Gut R.Z., HTRS Investigators. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: The experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004–2008). Haemophilia. 2012; 18: 990–6.
662. Santagostino E., Escobar M., Ozelo M., et al. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. Blood Rev. 2015; 29(Suppl 1): S9–18.
663. Shapiro A.D., Neufeld E.J., Blanchette V., et al. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: Overall rFVIIa exposure and intervals following high (> 240 mсg/kg) rFVIIa doses across clinical trials and registries. Haemophilia. 2014; 20: e23–31.
664. Valentino L.A., Holme P.A. Should antiinhibitor coagulant complex and tranexamic acid be used concomitantly? Haemophilia. 2015; 21: 709–14.
665. Matino D., Makris M., Dwan K., et al. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev. 2015; (12): CD004449.
666. Treur M.J., McCracken F., Heeg B., et al. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: A Bayesian metaregression. Haemophilia. 2009; 15: 420–36.
667. Collins P.W., Chalmers E., Hart D.P., et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013; 160: 153–70.
668. Caviglia H., Candela M., Galatro G., et al. Elective orthopaedic surgery for haemophilia patients with inhibitors: Single centre experience of 40 procedures and review of the literature. Haemophilia. 2011; 17: 910–9.
669. Ju H.Y., Jang H.L., Park Y.S. The effi cacy of bypassing agents in surgery of hemophilia patients with inhibitors. Blood Res. 2015; 50: 173–8.
670. Teitel J.M., Carcao M., Lillicrap D., et al. Orthopaedic surgery in haemophilia patients with inhibitors: A practical guide to haemostatic, surgical and rehabilitative care. Haemophilia. 2009; 15: 227–39.
671. Hay J.W., Zhou Z.Y. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa. J Med Econ. 2011; 14: 516–25.
672. Knight C., Dano A.M., Kennedy-Martin T. A systematic review of the costeffectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia. 2009; 15: 405–19.
673. Jimenez-Yuste V., Nunez R., Romero J.A., et al. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain. Haemophilia. 2013; 19: 841–6.
674. Giangrande P.L., Wilde J.T., Madan B., et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia. 2009; 15: 501–8.
675. Dargaud Y., Lienhart A., Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood. 2010; 116: 5734–7.
676. Furukawa S., Nogami K., Ogiwara K., et al. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. J Thromb Haemost. 2015; 13: 1279–84.
677. Aledort L.M. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004; 2: 1700–8.
678. O’Connell N.M., Riddell A.F., Pascoe G., et al. Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency. Haemophilia. 2008; 14: 775–81.
679. Neufeld E.J., Negrier C., Arkhammar P., et al. Safety update on the use of recombinant activated factor VII in approved indications. Blood Rev. 2015; 29(Suppl 1): S34–41.
680. Aledort L.M. Factor VIII inhibitor bypassing activity (FEIBA): Addressing safety issues. Haemophilia. 2008; 14: 39–43.
681. Cromwell C., Aledort L.M. FEIBA: A prohemostatic agent. Semin Thromb Hemost. 2012; 38: 265–7.
682. Knofl er R., Koscielny J., Tauer J.T., et al. Desmopressin testing in haemophilia A patients and carriers: Results of a multi centre survey. Hamostaseologie. 2012; 32: 271–5.
683. Seary M.E., Feldman D., Carcao M.D. DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotype. Haemophilia. 2012; 18: 50–5.
684. Di Perna C., Riccardi F., Franchini M., et al. Clinical effi cacy and determinants of response to treatment with desmopressin in mild hemophilia A. Semin Thromb Hemost. 2013; 39: 732–9.
685. Nance D., Fletcher S.N., Bolgiano D.C., et al. Factor VIII mutation and desmopressin-responsiveness in 62 patients with mild haemophilia A. Haemophilia. 2013; 19: 720–6.
686. Stoof S.C., Sanders Y.V., Petrij F., et al. Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia A. Thromb Haemost. 2013; 109: 440–9.
687. Stoof S.C., Sanders Y.V., Cnossen M.H., et al. Desmopressin response in hemophilia A patients with FVIII:C < 0.10 IU mL(-1.). J Thromb Haemost. 2014; 12: 110–2.
688. Tran H.T., Sorensen B., Rea C.J., et al. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. Haemophilia. 2014; 20: 369–75.
689. Rea C.J., Foley J.H., Bevan D.H., Sorensen B. An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A. Ann Hematol. 2014; 93: 683–92.
690. Dai L., Bevan D., Rangarajan S., et al. Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma. Haemophilia. 2011; 17: e944–8.
691. Ghosh K., Shetty S., Jijina F., Mohanty D. Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. Haemophilia. 2004; 10: 58–62.
692. Davis A., Walsh M., McCarthy P., et al. Tranexamic acid without prophylactic factor replacement for prevention of bleeding in hereditary bleeding disorder patients undergoing endoscopy: A pilot study. Haemophilia. 2013; 19: 583–9.
693. Hermans C., Hammer F., Lobet S., Lambert C. Subclinical deep venous thrombosis observed in 10 % of hemophilic patients undergoing major orthopedic surgery. J Thromb Haemost. 2010; 8: 1138–40.
694. Perez Botero J., Spoon D.B., Patnaik M.S., et al. Incidence of symptomatic venous thromboembolism in patients with hemophilia undergoing joint replacement surgery: A retrospective study. Thromb Res. 2015; 135: 109–13.
695. Pradhan S.M., Key N.S., Boggio L., Pruthi R. Venous thrombosis prophylaxis in haemophilics undergoing major orthopaedic surgery: A survey of haemophilia treatment centres. Haemophilia. 2009; 15: 1337–8.
696. Raza S., Kale G., Kim D., et al. Thromboprophylaxis and incidence of venous thromboembolism in patients with hemophilia A or B who underwent highrisk orthopedic surgeries. Clin Appl Thromb Hemost. 2016; 22: 161–5.
697. Mannucci P.M., Mauser-Bunschoten E.P. Cardiovascular disease in haemophilia patients: A contemporary issue. Haemophilia. 2010; 16(Suppl 3): 58–66.
698. Palla R., Peyvandi F., Shapiro A.D. Rare bleeding disorders: Diagnosis and treatment. Blood. 2015; 125: 2052–61.
699. Peyvandi F., Bolton-Maggs P.H., Batorova A., De Moerloose P. Rare bleeding disorders. Haemophilia. 2012; 18(Suppl 4): 148–53.
700. Castaman G. Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders. Blood Transfus. 2008; 6(Suppl 2): s39–44.
701. Kadir R., Chi C., Bolton-Maggs P. Pregnancy and rare bleeding disorders. Haemophilia. 2009; 15: 990–1005.
702. Van Geffen M., Menegatti M., Loof A., et al. Retrospective evaluation of bleeding tendency and simultaneous thrombin and plasmin generation in patients with rare bleeding disorders. Haemophilia. 2012; 18: 630–8.
703. Rugeri L., Quelin F., Chatard B., et al. Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. Haemophilia. 2010; 16: 771–7.
704. Zia A.N., Chitlur M., Rajpurkar M., et al. Thromboelastography identifies children with rare bleeding disorders and predicts bleeding phenotype. Haemophilia. 2015; 21: 124–32.
705. Mumford A.D., Ackroyd S., Alikhan R., et al. Guideline for the diagnosis and management of the rare coagulation disorders: A United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2014; 167: 304–26.
706. Bolton-Maggs P.H., Perry D.J., Chalmers E.A., et al. The rare coagulation disorders — review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia. 2004; 10: 593–628.
707. Lobel J.S., Majumdar S., Kovats-Bell S. Successful prophylactic treatment for bleeding in a girl with severe hereditary prothrombin deficiency using a prothrombin complex concentrate (Bebulin VH). J Pediatr Hematol Oncol. 2004; 26: 480–3.
708. Mathias M., Pollard D., Riddell A. Prophylaxis in severe prothrombin deficiency. Br J Haematol. 2011; 152: 243–4.
709. van Veen J.J., Hampton K.K., Maclean R., et al. Blood product support for delivery in severe factor X deficiency: The use of thrombin generation to guide therapy. Blood Transfus. 2007; 5: 204–9.
710. Barillari G., Pasca S., Gonano N., Daminato R. Prothrombin complex concentrate such as therapy and prophylaxis in factor X-deficient patient (Friuli variant). Clin Appl Thromb Hemost. 2011; 17: 332–6.
711. Peyvandi F., Palla R., Menegatti M., et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: Results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012; 10: 615–21.
712. Peyvandi F., Di Michele D., Bolton-Maggs P.H., et al. Classifi cation of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost. 2012; 10: 1938–43.
713. Salomon O., Steinberg D.M., Tamarin I., et al. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis. 2005; 16: 37–41.
714. Baumann Kreuziger L.M., Morton C.T., Reding M.T. Is prophylaxis required for delivery in women with factor VII deficiency? Haemophilia. 2013; 19: 827–32.
715. Siboni S.M., Biguzzi E., Pasta G., et al. Management of orthopaedic surgery in rare bleeding disorders. Haemophilia. 2014; 20: 693–701.
716. Santoro C., Di Mauro R., Baldacci E., et al. Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. Haemophilia. 2015; 21: 496–501.
717. Kreuz W., Meili E., Peter-Salonen K., et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci. 2005; 32: 247–53.
718. Peyvandi F., Haertel S., Knaub S., Mannucci P.M. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost. 2006; 4: 1634–7.
719. Peyvandi F. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. Thromb Res. 2009; 124(Suppl 2): S9–11.
720. Bornikova L., Peyvandi F., Allen G., et al. Fibrinogen replacement therapy for congenital fi brinogen defi ciency. J Thromb Haemost. 2011; 9: 1687–1704.
721. Benlakhal F., Mura T., Schved J.F., Giansily-Blaizot M. A retrospective analysis of 157 surgical procedures performed without replacement therapy in 83 unrelated factor VII-deficient patients. J Thromb Haemost. 2011; 9: 1149–56.
722. Mariani G., Dolce A., Batorova A., et al. Recombinant, activated factor VII for surgery in factor VII deficiency: A prospective evaluation: The surgical STER. Br J Haematol. 2011; 152: 340–6.
723. Mariani G., Dolce A., Napolitano M., et al. Invasive procedures and minor surgery in factor VII deficiency. Haemophilia. 2012; 18: e63–5.
724. Mariani G., Napolitano M., Dolce A., et al. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation. Thromb Haemost. 2013; 109: 238–47.
725. Mathias M., Tunstall O., Khair K., Liesner R. Management of surgical procedures in children with severe FV deficiency: experience of 13 surgeries. Haemophilia. 2013; 19: 256–8.
726. Napolitano M., Giansily-Blaizot M., Dolce A., et al. Prophylaxis in congenital factor VII deficiency: Indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica. 2013; 98: 538–44.
727. Windyga J., Zbikowski P., Ambroziak P., et al. Management of factor VII deficient patients undergoing joint surgeries — preliminary results of locally developed treatment regimen. Haemophilia. 2013; 19: 89–93.
728. Ashley C., Chang E., Davis J., et al. Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia. 2015; 21: 102–8.
729. Brenner B., Wiis J. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency. Hematology. 2007; 12: 55–62.
730. Busani S., Semeraro G., Cantaroni C., et al. Recombinant activated factor VII in critical bleeding after orthotopic liver transplantation. Transplant Proc. 2008; 40: 1989–90.
731. Schulman S., Tjonnfjord G.E., Wallensten R., et al. Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII. Thromb Haemost. 2005; 94: 1177–80.
732. Tran H.T., Tjonnfjord G.E., Paus A., Holme .PA. rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency. Haemophilia. 2011; 17: 764–70.
733. Napolitano M., Dolce A., Batorova A., et al. Replacement therapy in inherited factor VII deficiency: Occurrence of adverse events and relation with surgery. Haemophilia. 2015; 21: e513 7.
734. Kenet G., Lubetsky A., Luboshitz J., et al. Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitors. Haemophilia. 2009; 15: 1065–73.
735. Chi C., Kulkarni A., Lee C.A., Kadir R.A. The obstetric experience of women with factor XI deficiency. Acta Obstet Gynecol Scand. 2009; 88: 1095–1100.
736. Livnat T., Tamarin I., Mor Y., et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-defi cient patients with inhibitor antibodies. Thromb Haemost. 2009; 102: 487–92.
737. Franchini M., Manzato F., Salvagno G.L., et al. The use of desmopressin in congenital factor XI defi ciency: A systematic review. Ann Hematol. 2009; 88: 931–5.
738. Marty S., Barro C., Chatelain B., et al. The paradoxical association between inherited factor VII deficiency and venous thrombosis. Haemophilia. 2008; 14: 564–70.
739. Girolami A., de Marinis G.B., Bonamigo E., Lombardi A.M. Recombinant FVIIa concentrate-associated thrombotic events in congenital bleeding disorders other than hemophilias. Hematology. 2012; 17: 346–9.
740. Batty P., Honke A., Bowles L., et al. Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres. Haemophilia. 2015; 21: 490–5.
741. Ruiz-Saez A. Occurrence of thrombosis in rare bleeding disorders. Semin Thromb Hemost. 2013; 39: 684–92.
Рецензия
Для цитирования:
Kozek-Langenecker S.A., Ahmed А.B., Afshari A., Albaladejo P., Aldecoa C., Barauskas G., Robertis E.D., Faraoni D., Filipescu D.C., Fries D., Haas T., Jacob M., Lance´ M.D., Pitarch J.V., Mallett S., Meier J., Molnar Z.L., Rahe-Meyer N., Samama C.M., Stensballe J., Van der Linden P.J., Wikkelsø A., Wouters P., Wyffels P., Zacharowski K. Руководство по лечению тяжелого периоперационного кровотечения: рекомендации Европейского общества анестезиологов. Гематология и трансфузиология. 2021;66(1):88-160.
For citation:
Kozek-Langenecker S.A., Ahmed A.B., Afshari A., Albaladejo P., Aldecoa C., Barauskas G., Robertis E.D., Faraoni D., Filipescu D.C., Fries D., Haas T., Jacob M., Lance´ M.D., Pitarch J.V., Mallett S., Meier J., Molnar Z.L., Rahe-Meyer N., Samama C.M., Stensballe J., Van der Linden P.J., Wikkelsø A.J., Wouters P., Wyffels P., Zacharowski K. Management of severe perioperative bleeding. Guidelines from the European Society of Anaesthesiology. Russian journal of hematology and transfusiology. 2021;66(1):88-160. (In Russ.)
Просмотров: 1928
Послать статью по эл. почте 
